University of Missouri, St. Louis

IRL @ UMSL
Theses

Graduate Works

11-20-2015

Discovery and Metabolic Engineering of Steroid
Alkaloid Biosynthetic Genes from (Veratrum
californicum)
Megan M. Augustin
University of Missouri-St. Louis, megan.m.augustin@gmail.com

Follow this and additional works at: http://irl.umsl.edu/thesis
Part of the Biology Commons
Recommended Citation
Augustin, Megan M., "Discovery and Metabolic Engineering of Steroid Alkaloid Biosynthetic Genes from (Veratrum californicum)"
(2015). Theses. 17.
http://irl.umsl.edu/thesis/17

This Thesis is brought to you for free and open access by the Graduate Works at IRL @ UMSL. It has been accepted for inclusion in Theses by an
authorized administrator of IRL @ UMSL. For more information, please contact marvinh@umsl.edu.

Discovery and Metabolic Engineering of Steroid Alkaloid Biosynthetic Genes from Veratrum
californicum

By
Megan M. Augustin

B.S. Biology, University of Missouri-St. Louis, 2007
A.A. General Transfer Studies, St. Louis Community College-Florissant Valley,
2004

A Thesis
Submitted to The Graduate School of the
University of Missouri-St. Louis
in partial fulfillment of the requirements for the degree
Master of Science
In
Biology
With an emphasis in Molecular and Cellular Biology
December 2015

Advisory Committee
Wendy Olivas, Ph.D.
Chairperson
Bethany Zolman, Ph.D.

Toni M. Kutchan, Ph.D.

Augustin, Megan, 2015, UMSL, p.2

Abstract
The steroid alkaloid cyclopamine has shown much promise as a treatment for cancers in which
aberrant hedgehog signaling plays a role. The compound, originally discovered due to its
teratogenic effects in sheep, binds to the hedgehog signaling receptor Smoothend and prevents
downstream activation. As this pathway is primarily active during embryonic development,
overactivation later in life can lead to tumor formation and proliferation. Several studies have
shown that cyclopamine can inhibit and even reverse tumor growth, but limited supply will
prevent widespread use upon FDA approval of it or any of its semi-synthetic analogs. As high
value plant medicinal compounds are in demand, producing them at industrially feasible levels
is not always possible. Many plant natural products are originally produced in low quantities and
often from species that are not amendable to cultivation. Production of these compounds in a
heterologous system is ideal, but first the underlying genes that encode biosynthetic enzymes
must be discovered. Cyclopamine is produced in one of these non-ideal sources, the slow
growing Veratrum californicum, a species that has not been successfully cultivated. Our goal
was to discover the underlying genes in the biosynthetic pathway to cyclopamine and express
them in the emerging heterologous production system Camelina sativa. Herein, the first four
genes in the biosynthetic steroid alkaloid pathway to verazine, a hypothesized intermediate of
cyclopamine, have been discovered by correlating gene expression and alkaloid accumulation.
In addition, the genes have been successfully introduced into C. sativa under the control of seed
specific promoters for the production of V. californicum secondary metabolites in seed. Future
work requires discovery of the remaining cyclopamine biosynthetic genes and metabolic fine
tuning for increased metabolite yield, but the groundwork has been set for future work using C.
sativa as a production system for high value, medicinally significant, plant natural products.
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Chapter 1: History and introduction of cyclopamine
1.1 History of Veratrum californicum and cyclopamine
Peculiar birth defects ranging from pronounced lower jaw to full blown cyclopia were reported to
occur in lambs born in southwestern and south central Idaho from the early 1900-1950’s (Figure
1). The incidence of congenital anomalies occurred in up to 25% of offspring in some sheep
herds (Keeler 1978a). Frequencies were not necessarily accurate as some sheep herders failed
to report incidences due to fear of gaining a negative reputation of owning poor genetic stock.
Appropriate breeding practices, however, made genetic causes unlikely (Keeler 1978a). In
addition, reports of these birth defects appeared to correlate with grazing location as opposed to
specific breeding lines. Ranchers finally contacted the
Poison Plant Research Laboratory (PPRL) of the United
States Department of Agriculture in 1954 for help in
determining the cause behind the instances (Lee et al.
2014).
The PPRL, located in Logan, Utah, helped initially rule
out genetic causes through breeding experiments by
mating ewes known to have birthed deformed lambs with
their own rams (Binns et al. 1959).These results
indicated what was previously expected; the origin of the
birth defects was likely caused by foraging. Continued
investigation led researchers to conduct feeding trials based
upon a plant common to all ranges where the deformities were
reported. The malefactor was officially determined to be a
member of the Melanthiaceae/Liliaceae family (debated
phylogenetic placement), Veratrum californicum (false hellebore,
corn lily), a native plant frequently found in mountainous regions
of the Northwestern United States (Figure 2) (Binns et al. 1963,
Heretsch et al. 2010). A range in birth defects from mild to severe
was observed upon ingestion of V. californicum by pregnant
ewes, including holoprosencephaly (lack of division in forebrain),
single and double globe cyclopia containing only a single optic
nerve, and a proboscis emerging from the forehead. In addition,
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the upper palate was often missing in conjunction with a pronounced lower jaw. The most
severe cases resulted in aborted lambs (Binns et al. 1962, Keeler 1978a). Continued
investigation indicated that the birth defects correlated with the time of V. californicum ingestion.
The highest incidence of cyclops lambs occurred when V. californicum was consumed at day 14
of gestation, the time when the primitive streak develops in sheep (Binns et al. 1965).
Consumption of V. californicum at subsequent periods of gestation resulted in malformations of
the trachea, gut, and limbs (Lee et al. 2014). Now that the causative species and knowledge
concerning the time of insult for V. californicum exposure was revealed, ranchers could
minimize incidences of abnormal births by directing animal foraging. These practices have
successfully kept re-occurrences of birth defects due to V. californicum poisoning low (Keeler
1978b).
Even after the discovery of V. californicum as the cause of congenital abnormalities and
implementation of effective grazing management, researchers at the PPRL continued to search
for the precise teratogenic agent. Previous studies indicating the inhibitory effects that certain
steroidal alkaloids had on cell division hinted to researchers that this class of metabolites might
be of interest (Keeler 1978a). Initial investigations were conducted by testing fractions of
different V. californicum tissue extracts for teratogenicity. The compounds causing the
abnormalities were shown to be extractable by benzene/ammonia followed by ethanol (Keeler
and Binns 1966a, Keeler and Binns 1966b). Subsequently, steroidal alkaloids, both the
glycosides and parent alkamines from V. californicum, were extracted, purified, and tested for
teratogenicity in sheep. In addition, structurally related compounds were tested. Only three
steroidal alkaloids, obtained directly from V. californicum, were found to cause the teratogenic
effect of cyclopia in lambs. These included cyclopamine (1) (the most potent), cycloposine (2)
(glycoside of cyclopamine), and jervine (3) (Figure 3)(Keeler and Binns 1968). Additional testing
with other structurally related steroid based compounds including alkaloids, sapogenins, and
hormones were conducted in order to elucidate the exact structural component that conferred
teratogenicity. The results were not 100% conclusive, but point to the presence of the furan ring
and its respective ether bridge (Keeler 1970a). Further analysis of the teratogenicity of the
related steroidal alkaloid solasodine (4) provided evidence that the nitrogen in the F-ring was
required, and its projection in the alpha position may be essential. The basic nature of the
nitrogen is higher in cyclopamine, which may account for its greater teratogenic effects
compared to solasodine (Keeler et al. 1976). One early hypothesis concerning the teratogenicity
of cyclopamine included conversion to an active form in the gut of ruminant animals, but non-
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ruminant animals such rabbits, hamsters, rats, and mice were also susceptible to cyclopamine
poisoning (Binns et al. 1972, Keeler 1970b, Keeler 1975). In addition, direct application of
cyclopamine to developing embryos also caused teratogenic effects (Bryden and Keeler 1973,
Bryden et al. 1973).

Structural elucidation of cyclopamine was discovered first in Veratrum grandiflorum by a
research group in Japan (Masamune et al. 1964). It was unknown at the time that this
compound was identical to the compound causing cyclopic teratogenicity in lambs in the United
States. The structure was similar to the known structure jervine, only missing the ketone moiety
on the C-11 position, and therefore called 11-deoxojervine. The steroid alkaloid in V.
californicum was later confirmed to be identical to that in V. grandiflorum by the researchers at
the PPRL (Keeler 1969). Cyclopamine contains six rings (A-F) and possesses a C-nor-D-homo
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ring structure (Figure 3). The F-ring is a piperidine structure containing a secondary basic
nitrogen. The D-ring is connected to the tetrahydrofuran E ring by a spiro connection (Heretsch
et al. 2010). More information on steroid alkaloids and their structures is described below.
1.2 Diversity of steroid alkaloids
A few classes of plants and animals synthesize a wide range of structurally diverse and often
bioactive steroid alkaloids. The plant families containing the majority of steroid alkaloids (in bulk
and diversity) include Apocynaceae, Buxaceae, Liliaceae, and Solanaceae. Steroid alkaloids
have also been discovered in a few vertebrate species and marine animals. Marine
invertebrates including Zoanthid, Cephalodiscus, and Ritterella in addition to the amphibians
Salamandra (a genus of six salamanders), Bufo (true toads) and Phyllobates (a genus of poison
dart frogs) also contain steroid alkaloids. Many have been shown to have significant biological
activity including therapeutic benefits as well as microbial/fungal growth inhibition. The origin of
most steroid alkaloids derives from the triterpene skeletons cycloartenol, lanosterol, and
cholesterol, followed by a numerous combination of chemical alterations. Due to the steroid or
triterpene origin, they are often referred to as steroidal amines as opposed to true alkaloids that
derive from amino acids (Cordell 1998).
Members of the Apocynaceae family (including Holarrhena, Paravallaris, Funtumia, Kibatalia,
and Malouetia) generally produce steroid alkaloids of two basic types, the conanine-type (5) and
pregnane-type (6) (Figure 4). The pregnane-type is medicinally useful as alkaloids of this class
may be converted to steroid hormones. Other biological activities from Apocynaceae alkaloids
include activity against amoebiasis conferred by the conanine-type steroid alkaloid conessine
and hepatocarcinogenesis conferred by the pregnane-type steroid alkaloid irehdiamine-A
(Cordell 1998).
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Several genera of the Buxaceae are known to contain steroid alkaloids including Buxus,
Sarcococca, and Pachysandra. There are two main skeletal structures found in this family
(Figure 4) one including a characteristic cyclopropane ring (7) and one that does not (8).
Structures of these classes often contain methyl groups at one or both C-4 and C-14 positions,
making them intermediates between cholesterol and lanosterol type steroids. Some genera also
contain the pregnane-type steroid alkaloids. Extracts of boxwood (Buxus sempervirens) contain
the steroid alkaloids cyclobuxine-D and buxamine, and have exhibited medicinal effects against
several ailments including malaria, syphilis, cancer, and tuberculosis (Cordell 1998).
Genera of the Liliaceae known to contain steroid alkaloids include Veratrum, Fritillaria, Petilium,
Zygadenus, and Korolkowia. Three general classes of steroid alkaloids are found in the
Liliaceae including the cerveratrum-type, jerveratrum-type, and the solanidine-type. These
classes can be further divided into 5 distinct groups, the cevanine-type (9) (cerveratrum-type),
the veratramine-type (10) (distinct from jerveratrum-type as it lacks the ether bridge of jervine),
the jervine-type (11), the solanidine-type (12), and the verazine-type (13) (distinct from the
solanidine-type as it contains only 5 rings) (Figure 4) (Li et al. 2006). Compounds containing the
ring structure similar to cholesterol (6-6-6-5) are considered steroid alkaloids (the solanidine and
verazine-types) and compounds containing a C-nor-D-homo ring system (6-6-5-6) are
considered isosteroid alkaloids (cevanine, veratramine, and jervine types). The designation Cnor-D-homo refers to the C-ring having one less carbon (‘nor’) and the D-ring having an
additional carbon (‘homo’). Cyclopamine falls into the jervine-type as it possesses a hexacyclic
skeletal system with a C-nor-D-homo ring structure in addition to an ether bridge between the D
and F-rings, forming the tetrohydrofuran E-ring. In addition, a spiro connection is found between
D and E-ring at the C-17 position. Cevanine-type alkaloids are highly hydroxylated with a
distinctive C-4, C-9 linkage between the A and B-rings. Alkaloids of the veratramine type are
missing the ether bridge and therefore lack a 6th ring in conjunction with a characteristic
aromatic D-ring (Cordell 1998). Plants of these genera have been used in traditional medicines
to treat ailments including toothache, sore throat, venereal diseases, wounds, epilepsy, and
cardiac disease. In addition, crushed Veratrum viride rhizome was applied to snakebites and the
European Veratrum species V. album was known for its emetic properties. Treatment of
hypertension with the steroid alkaloid protoveratrine is also known (Chandler and McDougal
2014).
Five types of steroid alkaloids found in the Solanaceae (including the genera Solanum and
Lycopersicon) are the solanidine-type (12), spirosolane-type (14), solacongestidine-type (15)
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solanocapsine-type (16), and jurbidine-type (17) (Figure 4). The solacongestidine-type is
essentially the same as the verazine-type, but different sources have slightly different
classifications, so both are relevant terms. Medicinal value from Solanaceae alkaloids is marked
as they can serve as precursors to steroidal hormones. Antimicrobial activity has also been
detected from several compounds (Cordell 1998). In addition, α-tomatine, a glycosylated steroid
alkaloid from Lycopersicon esculentum, has exhibited antineoplastic activity in prostate cancer
cells (Lee et al. 2011, Lee et al. 2013a, Lee et al. 2013b).
The distinct types of steroid alkaloids are not necessarily unique to each genus as several
alkaloids of the same type can be found among the different families. For example, the
solanidine and verazine-type can be found in the Liliaceae and the Solanaceae. Also, the
pregnane-type is found in both the Apocynaceae and Buxaceae. However, the cevanine,
veratramine, and jervine-types that contain the characteristic C-nor-D-homo ring structure are,
so far, found exclusively in the Liliaceae (Cordell 1998).
Steroid alkaloids from the animal kingdom can also differ markedly from those found in the plant
kingdom. For example, the structurally distinct samandarin (18) is a characteristic steroid
alkaloid from Salamandra species containing an expanded A ring (Figure 4). Also of note, the
nitrogen atom was found to derive from glutamine, contradictory to the predicted source for
nitrogen for steroid alkaloids in plants (discussed below). Also quite distinct from the steroid
alkaloids in plants are those found in marine organisms. These include the novel dimeric steroid
backbones like that found in cephalostatin (19) (Figure 4) (Cordell 1998).
1.3 Hedgehog signaling and cyclopamine
1.3.1 Discovery of hedgehog pathway
The teratogenic effect of cyclopamine was eventually discovered in the late 1990s. Inhibition of
Hedgehog (Hh) signaling in developing embryos resulted in the craniofacial birth defects
observed (Incardona et al. 1998). The Hh pathway was originally discovered in Heidelberg at
the European Molecular Biology Laboratory in the late 1970s by Nüsslein-Volhard and
Wieschaus during mutational studies and their effects on embryogenesis in Drosophila
melanogaster. In D. melanogaster, this signaling pathway is primarily responsible for
segmentation and development of the body plan. One of the fifty mutants in the screen resulted
in larva covered in epidermal spikes. This mutant led to the naming, cloning, and identification of
the first Hh gene.
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The Hh signaling pathway is highly conserved from flies to mammals as it plays a predominate
role in embryonic development. It is responsible for many developmental processes in
mammals including formation of the limbs, nervous system, teeth, lungs, intestine, cartilage, and
sperm and is heavily involved in bilateral symmetry. Three well conserved homologs to the D.
melanogaster Hh gene exist in mammals; Sonic Hedgehog (Shh), Desert Hedgehog (Dhh), and
Indian Hedgehog (Ihh). Each are involved in unique processes, with Shh being the most
abundant ligand, having the
broadest expression and influence
and being the most well studied
(Heretsch et al. 2010, Lee et al.
2014). The hedgehog signaling
pathway is primarily silenced in
adults, but reactivation can occur for
regeneration and injury repair.
Aberrant overactivation can lead to
uncontrolled cell growth and
oncogenesis (McMillan and Matsui
2012). Cyclopamine inhibition of the
Hh pathway has been shown to
downregulate overactivation,
stopping and even reversing
tumorigenesis caused by abnormal
signaling (Taipale et al. 2000).
1.3.2 Canonical hedgehog signaling
Canonical hedgehog signaling is activated by the presence of the Hh ligands (Shh, Ihh, and Dhh
in mammals). Initially, the signal sequence is removed from the nascent Hh peptide to yield a
~45 kD Hh precursor protein. Then, activation of the ligand begins when the protein undergoes
autocatalytic-cleavage initiated by the C-terminal domain leaving a 20 kD N-terminal domain
and a 25 kD C-terminal domain. In addition, a cholesterol moiety is added to the C-terminal end
of the N-terminal fragment. The C-terminal fragment functions solely in processing while the Nterminal fragment serves as the signaling molecule. The cholesterol modification results in
association of the Hh signaling peptide with the membrane, allowing the addition of a palmitoyl
moiety to the N-terminal end by Skinny Hedgehog (Ski), an acetyl transferase protein. The final
result is an active signaling molecule (Porter et al. 1996, Varjosalo and Taipale 2007). In the
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absence of active Hh, the 12-transmembrane receptor Patched (PTCH) represses the Hh
pathway by preventing the 7-transmembrane G-protein coupled receptor-like Smoothened
(SMO) from entering the primary cilium, a specialized cellular projection involved in signaling.
Upon activation by Hh signaling proteins, PTCH leaves the primary cilium and is degraded by
endosomes, resulting in an accumulation of SMO in the primary cilium and activation of the
pathway (Corbit et al. 2005, Peluso et al. 2014, Rohatgi and Scott 2007). Ligand binding to one
of the co-receptors of PTCH (CDO, BOC, or GAS1) is also required for activation (Izzi et al.
2011). Once SMO is active, it prevents the proteolytic processing of Gli2/3 (zinc finger
transcription factors) to their repressor forms by inhibiting the negative regulator Suppresser of
Fused (SUFU), Casein Kinase 1(CK1) Protein Kinase A (PKA), and Glycogen Synthase Kinase
3β (GSK3β) (Cochrane et al. 2015, Hui and Angers 2011). In the absence of signal, Gli2/3 are
processed into truncated forms that serve as repressors of the hedgehog target genes.
Therefore, active forms of Gli2/3 induce expression of hedgehog response genes. In addition, a
positive feedback loop is initiated as active Gli2/3 induce expression of Gli1, a protein involved
in amplification of the signal. PTCH expression is also induced by hedgehog pathway activation,
serving to downregulate the signal, thereby playing an opposing role to Gli1 (Figure 5) (Hui and
Angers 2011, McMillan and Matsui 2012, Niewiadomski et al. 2014).
1.3.3 Mechanism of hedgehog inhibition by cyclopamine
The exact mechanism of Hh signaling inhibition by cyclopamine was discovered by the research
group of Philip Beachy at the Johns Hopkins University School of Medicine with the help of
collaborators at the Howard Hughes Medical Institute. Beachy’s group was studying hedgehog
signaling in mammals and generated a cyclops mouse upon mutation of the Shh gene. The
connection was then made between the outbreaks of cyclops lambs in the 1950’s and Hh
signaling. Searching for an efficient way to control Hh signaling, his group turned to
cyclopamine, the causative agent of the teratogenic effects leading to cyclopia (Heretsch et al.
2010, Keeler and Binns 1968). Beachy’s group first hypothesized that cyclopamine inhibited
cholesterol biosynthesis, but it was shown that signal transduction was perturbed and the
synthesis of cholesterol was not involved (Cooper et al. 1998, Incardona et al. 1998). In the end,
their research showed that hedgehog signaling was inhibited when cyclopamine bound directly
to SMO and prevented downstream signaling, regardless of Hh ligands(Chen et al. 2002). More
recent work has shown that native oxysterols bind to the extracellular domain of SMO and are
required for its ability to send downstream signals. This binding site is distinct from that bound
by cyclopamine, however, as cyclopamine binds to the heptahelical bundle, a transmembrane
region of SMO (Nachtergaele et al. 2012, Nedelcu et al. 2013, Sharpe et al. 2015).
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1.3.4 Abnormal hedgehog signaling and cancer
Indication of the relationship between the development of cancer and abnormal signaling of the
Hh pathway originated in patients with the autosomal dominant Gorlin syndrome (Basal-cell
nevus syndrome). Patients suffering from Gorlin syndrome have skeletal abnormalities, basal
cell carcinomas, cysts, and cleft lip/palate in addition to other neoplasms and birth defects
(Gorlin 1995). It was discovered that this syndrome could be attributed to germline mutations in
PTCH, and therefore abnormal Hh signaling (Hahn et al. 1996, Johnson et al. 1996). Mutations
in PTCH have also been identified in up to 90% of sporadic basal cell carcinomas (Epstein
2008). In addition to Gorlin syndrome and basal cell carcinomas, development of
medulloblastoma has also been associated with reduced function of PTCH (Corcoran and Scott
2001, Wechsler-Reya and Scott 2001).
Aberrant Hh signaling has been subsequently shown to be involved in the development and
progression of numerous cancers through several mechanisms. One mechanism is through
ligand-independent constitutive activation. In this mechanism, overactivation of the Hh pathway
occurs regardless of Hh signaling protein. Mutations in PTCH (e.g. Gorlin syndrome and
medulloblastoma), SMO, or SUFU can fall into this category. Other mechanisms include
autocrine ligand-dependent (cells respond to over production of its own Hh signal) and
paracrine ligand-dependent (cells respond to overproduction of Hh signals from nearby cells).
More evidence supports the involvement of paracrine signaling in cancer growth, highlighting
the importance of the nearby stromal cells (connective tissue) and the surrounding
microenvironment. Some research, however, has shown the possibility of autocrine signaling
playing a role in acute lymphocytic leukemia (Lin and Matsui 2012, Lin et al. 2010, Yauch et al.
2008).
Ligand-dependent overactivation of the Hh pathway has been found to play a role in more
cancer types than ligand-independent overactivation. Production of Hh paracrine factors from
stromal cells was discovered to assist in the survival of B-cell malignancies, demonstrating the
importance of the microenvironment in tumor production (Dierks et al. 2007). Overexpression of
Shh was observed in 70% of pancreata samples from patients with pancreatic carcinoma
indicating a loss of Hh regulation. This misregulation was not attributed to mutations in PTCH,
SMO, or SUFU and is therefore ligand-dependent. Expression of PTCH, not detected in normal
pancreata cells, was also seen in abnormal epithelium and the surrounding mesenchymal cells
(Thayer et al. 2003). Ligand-dependent overactivation of Hh pathway was also observed in
some digestive tract cancers, small cell lung cancers, myeloid leukemia, multiple myeloma,
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colon cancer, melanomas, and prostate cancers (Berman et al. 2003, Karhadkar et al. 2004,
Peacock et al. 2007, Stecca et al. 2007, Varnat et al. 2009, Watkins et al. 2003, Zhao et al.
2009). Aberrant Hedgehog signaling was also observed in malignant pleural mesothelioma (Shi
et al. 2012).
Abnormal Hedgehog signaling is also involved in the proliferation and maintenance of cancer
stem cells. Using multiple myeloma as a model, researchers discovered the requirement of Hh
signaling in proliferation of tumor stem cells. The presence of Hh was also necessary to keep
the stem cells in an undifferentiated state (Peacock et al. 2007). The role of Hh signaling has
also been established in colon cancer stem cells and myeloid leukemia stem cells (Batsaikhan
et al. 2014, Varnat et al. 2009, Zhao et al. 2009). Cancer stem cells are attributed to the
reoccurrence of many cancers and are a particularly important target of cancer treatment.
1.3.5 Hedgehog signaling inhibition as cancer treatment
Inhibition of hedgehog signaling in many cancers where abnormal regulation is implicated has
shown great promise. Treatment of medulloblastoma cell cultures with cyclopamine showed
specific inhibition and reduction of tumor cell lines by up to 80% while fibroblast cells were
unaffected (Berman et al. 2002). In another study, cell death and decreased tumor size was
observed in a medulloblastoma mouse model by preventing hedgehog signaling (Romer et al.
2004). In prostate cancer, overexpression of PTCH was observed up to 400-fold the normal
levels in cancer cells as compared to benign epithelial cells. Treatment with cyclopamine
reversed these effects and inhibited growth in three out of four cell lines tested. In the same
study, cyclopamine treatment of prostate tumors in mouse models showed suppression and
regression. Discovery that Hh pathway activation is required in prostate cancer stem cells in
conjunction with the observed tumor regression indicates the cancer stem cells were also
effectively treated with cyclopamine (Karhadkar et al. 2004). Increased expression of Hh
pathway target genes was also observed in colon cancer cells, with a marked increase in
metastatic tumors. Treatment of colon cancer with cyclopamine inhibited hedgehog signaling,
caused reduced cell proliferation, increase apoptosis, and even eliminated tumors in mouse
models for up to one year when treated for 20 days. Treatment of melanoma cultures with
cyclopamine for 20 days also caused cancer cell death and prevented tumor recovery. Shorter
treatment periods in the colon cancer study initially eliminated tumors but regrowth was
observed, highlighting the necessity of Hh signaling for tumor reoccurrence (Stecca et al. 2007,
Varnat et al. 2009). A reduction in the expression of stem cell specific genes was also seen
when colon cancer cell cultures were treated with cyclopamine, indicating a possible role in
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treatment for colon cancer stem cells (Batsaikhan et al. 2014). As for pancreatic cancer,
cyclopamine treatment was found effective in 50% of cancer cell lines tested. Cyclopamine
induced apoptosis, reduced cell density, and tumor mass was reduced up to 60% in a mouse
model (Thayer et al. 2003). Treatment of mouse models with myeloid leukemia showed a 14fold reduction in cancer stem cells. In addition, 60% of cyclopamine-treated mice were alive
after 7 weeks while the control mice did not survive over 4 weeks. It was also noted that earlier
treatment with cyclopamine was more effective (Zhao et al. 2009) In research with multiple
myeloma, treatment with cyclopamine inhibited overactivation of Hh pathway and diminished
clonal capacity of cancer stem cells (Peacock et al. 2007). Another study showed complete
abolition of lymphoma cancer cells grown on a layer of non-cancerous stromal cells within 48
hours while the stromal cells were unaffected (Dierks et al. 2007). Targeted inhibition of the Hh
pathway in cancer cells vs. normal cells by cyclopamine and the marked effects on cancer stem
cells shows positive attributes for future cancer treatment.
Further elaboration on the importance of the microenvironment in tumor growth and its potential
as a therapeutic target was highlighted in two contradictory studies involving the effects of
cyclopamine / IPI-926 and pancreatic cancer. In one study, the treatment of pancreatic tumors
with cyclopamine showed a significant reduction of 42% in microvascular density. Angiogenesis
(growth of new blood vessels) was inhibited and the remaining tumor vasculature was narrow
and fragmented (Nakamura et al. 2010). A study published one year earlier, however, found that
treatment with the cyclopamine analog IPI-926 increased the vascular density and increased the
delivery of the chemotherapeutic agent gemcitabine (Olive et al. 2009). This could possibly be
due to the difference between cyclopamine and its analog, but the actual effects on cyclopamine
and growth of vasculature are still debated.
Several structural variations of cyclopamine have been designed for better solubility and stability
in order to increase its effectiveness as a cancer treatment. The double bond between C-12 and
C-13 creates an allylic oxygen in the furan ring, thus acid treatment (as would be encountered in
the stomach) will cause a break in the ether bridge, followed by aromatization of the D ring
resulting in toxic veratramine. KAAD-cyclopamine (20) (Figure 6), an analog with an attachment
to the nitrogen, was shown to have 10-20 times the potency of cyclopamine (Taipale et al.
2000). Carbohydrate derivatives of cyclopamine prepared with glycosyl azides in a manner
called “Click Chemistry” (easy chemical modifications under mild conditions) was utilized in an
attempt to increase solubility. Only one compound of the several tested came close to the
activity of cyclopamine (Zhang et al. 2008). In attempts to diminish the potential toxic side
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effects of cyclopamine on non-cancer cells,
some groups have developed cyclopamine
prodrugs. In one study, cyclopamine was
conjugated to a protein cleavable by
prostate-specific antigen (PSA), a serine
protease that is highly expressed in
prostate cells; cyclopamine is only
activated in these cells. A 7-fold
enhancement of the cyclopamine derivative
was detected in the presence of PSA as
opposed to controls without PSA (Kumar et
al. 2008). Another group designed a
cyclopamine analog bearing a glycosylated
poly(ethylene glycol) side chain that is
cleaved by β-glucuronidase, an enzyme
known to be highly concentrated in necrotic
areas of many tumors (Renoux et al.
2011). None of these analogs have, so far,
progressed passed the research laboratory.
Another promising cyclopamine derivative is IPI-926 (21) (Figure 6), advanced by Infinity
Pharmaceuticals from a batch of semi-synthetic derivatives including the seven-membered-ring
containing analog IPI-269609. This molecule showed increased solubility and stability with
positive results in lab settings. Complete regression of a medulloblastoma model was observed
in tumor bearing mice treated orally IPI-926 as opposed to cyclopamine treatments which
showed little effect under these conditions (Tremblay et al. 2009). Initial clinical trials also
showed positive results for patients with basal cell carcinomas (Jimeno et al. 2013). Less
promising results were obtained, however, in Phase 1b/II clinical trials for IPI-926 treatment of
pancreatic cancer in conjunction with Gemcitabine and Phase II clinical trials with myelofibrosis.
Both studies were terminated early as patients either had a lower median survival rate than the
controls or showed no improvement (Lee et al. 2014). Another Phase I clinical trial is currently
recruiting participants for IPI-926 in conjunction the chemotherapeutic drug FOLFIRINOX (Ko
2015). Despite setbacks, overall results for the hedgehog inhibitor cyclopamine and its analogs
are positive. Due to the complex nature of cancer metastasis, more clinical trials are required
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before abandoning this potential treatment. All of these cyclopamine derivatives, however,
require cyclopamine as starting material, so the need for cyclopamine supply is still great.
Recently, another structurally unrelated Hh antagonist, GDC-0449 (Vismodegib), was approved
by the FDA for use in adults with basal cell carcinoma. This is the first drug approved for cancer
treatment by perturbation of the Hh pathway. Mutations in cancer cells are common, and
multiple treatment options are required. Other cyclopamine analogs and unrelated Hh inhibitors
have been in development (Ma et al. 2013). The FDA approval of GDC-0449, the continued
synthesis of more stable, active, and biologically available Hh inhibitors, and the ongoing testing
of IPI-926 supports cancer therapy by Hh signaling inhibition and highlights the need for more
research in this field.
1.4 Cyclopamine supply
The promising activity of cyclopamine and its derivatives for cancer treatment is complicated by
the limited supply. The natural source, V. californicum, is a slow growing plant for which reliable
and robust propagation techniques are yet to be established (Song et al. 2014). Improved
extraction techniques have been developed, but issues include substantial benzene
consumption in addition to the limited supply of material. Total synthesis is difficult and
inefficient, with the most promising technique yielding only 1% cyclopamine. If cyclopamine or
any of its derivatives are approved for medicinal use, the current supply will not meet the
demand (Heretsch et al. 2010). Understanding how V. californicum produces cyclopamine is
one way to propel industrial production. Once the genes producing enzymes that are involved in
the chemical transformations of cyclopamine are discovered, they can be introduced into
another, more suitable, organism for production.
1.5 Current knowledge of steroid alkaloid biosynthesis
Little is known about the biosynthesis of steroid alkaloids, especially at the gene level. Early
studies performed in Japan during the 1970’s lead by Kaneko et al. provided a framework for
steroid alkaloid biosynthesis (including cyclopamine) in V. grandiflorum, but no genes were
identified (Figure 7). Possible intermediates for cyclopamine, including 22, 26dihydroxycholesterol (dormantinol), 22-keto-26-hydroxycholesterol (dormantinone), verazine,
and solanidine, were established based upon structure and their presence in the plant (Kaneko
et al. 1978, Kaneko et al. 1979, Kaneko et al. 1970a, Kaneko et al. 1970b, Kaneko et al. 1975,
Kaneko et al. 1977). Acetate and cholesterol were also established as early precursors by
feeding their 14C labeled counterparts to V. grandiflorum and monitoring incorporation into
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steroid alkaloids (Kaneko et al. 1970b). In addition, L-arginine was identified as the source of
nitrogen in the piperidine ring. The accumulation of L-arginine in the rhizome followed by a
significant decrease over time correlated with the accumulation of verazine(Kaneko et al. 1976).
Mechanistically, the closing of the E-ring is hypothesized to occur when the lone pair of
electrons on the nitrogen of teinemine undergoes a nucleophilic attack on the C-16 in the
presence of a suitable leaving group. Another experiment revealed the conversion between the
solanidine and jerveratrum alkaloids may require light. Etiolated V. grandiflorum plants
accumulated radioactive solanidyl glycoside when grown in the dark. When illuminated, they
started to accumulate radioactive jerveratrum alkaloids. In addition, this information supports a
Wagner-Meerwein rearrangement, which would require ATP (Heretsch et al. 2010, Kaneko et
al. 1979, Kaneko et al. 1972). Interestingly, one study based on the biosynthesis of solasodine
in Solanum laciniatum indicates the addition of nitrogen directly follows hydroxylation at the C26 position, then possibly functionalization at positon 22 (Tschesche and Brennecke 1980). This
contradiction, however, could be attributed to different pathways in the two species.
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More recently, work on the biosynthesis of α-tomatine, a spirosolane steroid alkaloid from S.
lycopersicum, has provided some insight on steroid alkaloid biosynthesis at the gene level.
Researchers used RNAi to downregulate potential biosynthetic genes (based on expression
correlation studies) and confirmed their functionality by analyzing accumulation of intermediates.
They found that hydroxylation of cholesterol at position C-22 was followed by hydroxylation at
position C-26 and that these reactions involved cytochrome P450 (CYP450) enzymes. Several
steps followed to form the E-ring which involves, at least, a CYP450 and a 2-oxoglutaratedependent dioxygenase. Oxidation at position C-26 was also catalyzed by a CYP450 followed
by addition of an amino group by a transaminase. Members of Solanaceae do not produce
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jerveratrum alkaloids containing the C-nor-D-homo ring system, however, the study does
provide information on enzyme classes involved and potential order of transformations.
1.6 Hypothesis and proposal
The issue remains that all genes involved in the biosynthesis of cyclopamine are unknown.
Knowledge of the underlying genes is essential for bioengineering the pathway into another,
more suitable, biological production system. Our goal is to discover the genes in the
biosynthetic pathway to cyclopamine and engineer the pathway into the emerging oilseed crop
Camelina sativa, chosen for its robust growth, low input requirements, and ease of
transformation (Bansal and Durrett 2015). We hypothesize that correlating a cyclopamine
accumulation model (based upon the concentration of cyclopamine in different V. californicum
tissues) with gene expression (obtained by Illumina high-throughput sequencing); we can
reduce the number of candidate genes to an acceptable level for functional characterization.
Candidate genes will be selected based upon correlation with the cyclopamine accumulation
model in conjunction with predicted functional annotation. Genes will be expressed in an Sf9
insect cell culture system to produce enzymes for testing. Functional enzymes will then be
transformed into C. sativa and driven by seed specific promoters in order to accumulate V.
californicum metabolites in seed. This will be the first attempt to discover cyclopamine
biosynthetic enzymes and to engineer C. sativa for medicinally useful metabolites.
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2.1 Summary
Steroid alkaloids have been shown to elicit a wide range of pharmacological effects that include
anticancer and antifungal activities. Understanding the biosynthesis of these molecules is
essential to bioengineering for sustainable production. Herein, we investigate the biosynthetic
pathway to cyclopamine, a steroid alkaloid that shows promising antineoplastic activities. Supply
of cyclopamine is limited, as the current source is solely derived from wild collection of the plant
Veratrum californicum. To elucidate the early stages of the pathway to cyclopamine, we
interrogated a V. californicum RNA-seq dataset using the cyclopamine accumulation profile as a
predefined model for gene expression with the pattern-matching algorithm Haystack.
Refactoring candidate genes in Sf9 insect cells led to discovery of four enzymes that catalyze
the first six steps in steroid alkaloid biosynthesis to produce verazine, a predicted precursor to
cyclopamine. Three of the enzymes are cytochromes P450 while the fourth is a γ-aminobutyrate
transaminase; together they produce verazine from cholesterol.
2.2 Significance statement
The first four enzymes involved in the biosynthesis of the steroid alkaloid verazine, a predicted
precursor to the antineoplastic cyclopamine in Veratrum californicum, were discovered:
cholesterol 22-hydroxylase, 22-hydroxycholesterol 26-hydroxylase/oxidase, 22hydroxycholesterol-26-al transaminase, and 22-hydroxy-26-aminocholesterol 22-oxidase. The
pathway to verazine has been refactored in Spodoptera frugiperda Sf9 cells.
2.3 Author contributions
D.A.M. collected V. californicum plant material. M.M.A isolated V. californicum RNA. D.R.R.
analyzed transcriptome data and produced the candidate gene list. D.R.R., A.K.S, and M.M.A.
cloned candidates into baculovirus expression vectors and expressed them in Sf9 cells. J.M.A.
and M.M.A. developed and performed enzyme assays to determine enzymatic activity and
purified metabolites for structure elucidation. C.M.S. and M.O.J. purified metabolites and
determined structures by NMR. B.S.E analyzed metabolites by LTQ-Velos Pro Orbitrap. M.R.M.
performed deep phylogenetic analysis of cytochromes P450. J.C.P., P.P.E., M.D.B., A.S.,
G.K.W., and M.K.D. contributed plant materials and RNAseq data from the 1KP project. M.M.A.
and T.M.K. analyzed data and wrote the manuscript, which was reviewed by all authors. T.M.K.
directed the study.
More specifically, I (M.M.A.) cloned contigs 13284 and 12709 and all of their respective
homologs, and homologs of 2646 (originally cloned by D.R.R.). I also cloned additional genes
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as indicated in Table S3 and verified the sequences of all genes by DNA sequencing. I
performed homologous recombination of genes 13284 (and the respective homologs), two
homologs of 12084, and one homolog of 2646 with baculovirus viral DNA in addition to those
indicated in Table S3. I performed all Sf9 cell maintenance and infection for enzyme production.
I conducted all enzyme assays and Sf9 extracts, ran all instruments and analyzed all data for
enzyme function and product production. I produced the data for and assembled the images for
figures 1,2,4,5 and supplemental figures S1-S8, S10-S15, and S17. I produced or assembled
information for tables S5-S7, and S11-S13. I wrote and edited this manuscript with the help of
Toni M. Kutchan.
2.4 Introduction
Plants synthesize numerous specialized metabolites that are used in medicines today (Mishra
and Tiwari 2011). Their endogenous function is thought to play a role in communication of the
plant with its environment, as these compounds possess an array of biological activities
(Mithofer and Boland 2012, Mizutani 2012). An understanding of how these molecules are
formed serves a dual role: enabling study of the in planta function, as well as development of
synthetic biology production platforms for source plants that are not amenable to cultivation or
genetic manipulation.
In seeking medicines from natural sources, plants synthesizing the nitrogen containing alkaloids
have proven to be a vital source. Of particular pharmaceutical interest are the steroid alkaloids.
Members of the families Liliaceae, Apocynaceae, Buxaceae, and Solanaceae are a rich source
of these alkaloids. The structural similarity of steroid alkaloids to mammalian steroid hormones
may be responsible for their therapeutic effects (Cordell 1998, Jiang et al. 2005, Zhou 2003).
Our study focuses on the steroid alkaloid cyclopamine from the Liliaceae family. Members of
Liliaceae contain three sub-classes of steroidal alkaloids: the jerveratrum-type, the cerveratrumtype, and the solanidine-type (Cordell 1998). Cyclopamine, also known as 11-deoxojervine, is a
jerveratrum-type alkaloid that exhibits potent pharmacological properties.
Cyclopamine was originally discovered due to its teratogenic effect that resulted in craniofacial
anomalies (cyclopia) in lambs born at high elevation in the northwestern United States in the
middle of the 20th century (Keeler 1970a, Keeler 1970b, Keeler and Binns 1966b). Studies
supported by the United States Department of Agriculture found that the California corn lily
Veratrum californicum was the source of the teratogen in the natural diet of the pregnant ewes
(Keeler 1968, Keeler 1969, Keeler 1970a). Cyclopamine was discovered to inhibit the
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Hedgehog signaling pathway by direct binding to the G protein-coupled receptor Smoothened
(Chen et al. 2002). As such, cyclopamine has shown promising antineoplastic activities against
several cancers in which Hedgehog signaling malfunction is implicated, including pancreatic
cancer, renal cell carcinoma, medulloblastoma, basal cell carcinoma, and leukemia (Bahra et al.
2012, Behnsawy et al. 2013, Berman et al. 2002, Gailani et al. 1996, Lin et al. 2010, Olive et al.
2009, Taipale et al. 2000). A semi-synthetic analog of cyclopamine, IPI-926, has been in clinical
trials for treatment of several cancers including pancreatic cancer and leukemia (Lin et al. 2010,
Olive et al. 2009, Tremblay et al. 2009). Due to complicated total synthesis, wild-collected V.
californicum is the current commercial source of cyclopamine. Commercial cultivation of the
plant has not yet been successful. Cyclopamine is thereby an attractive target for
biotechnological production. The first obstacle to this approach is, however, obtaining
knowledge of the underlying biosynthetic genes.
Cyclopamine biosynthesis is believed to begin with cholesterol, a common precursor to most
steroidal alkaloids (Cordell 1998, Kaneko et al. 1970b). Early studies on species of the Liliaceae
and Solanaceae families have proposed transformation of cholesterol to metabolites identified in
plant extracts that include dormantinol, dormantinone, verazine, and etioline. All of these
molecules are proposed intermediates in the biosynthesis of cyclopamine (Chandler and
McDougal 2014, Kaneko et al. 1977). Previous feeding studies shed limited light on pathway
order and suggested that L-arginine is the origin of the nitrogen atom (Kaneko et al. 1977,
Kaneko et al. 1976, Tschesche and Brennecke 1980). A more recent report on the biosynthesis
of Solanaceous alkaloids utilizing gene co-expression analysis and RNAi knock-out transgenic
plants in Solanum tuberosum and Solanum lycopersicum outlines a biosynthetic pathway
leading to the synthesis of the spirosolane-type steroid alkaloid α-tomatine. The enzyme classes
identified in the Solanum pathway include several cytochrome P450 enzymes, a transaminase,
and a 2-oxoglutarate-dependent dioxygenase (Itkin et al. 2013). Questions remain, however,
concerning the formation of steroid alkaloids in Veratrum as no genes or enzymes have been
reported.
Biochemical pathway elucidation in non-model systems has historically taken decades to
complete, but bioinformatic technologies are revolutionizing the approach. A prominent example
of former methods used in pathway discovery is morphine biosynthesis in opium poppy,
Papaver somniferum. Though morphine was discovered in the early 1800’s, the biosynthetic
pathway is still incomplete at the gene level. Genes encoding only 6 of the 8 enzymes
committed to the biosynthesis of morphine have been isolated and characterized from the
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1990’s to the present – several decades of work to uncover fewer than 8 genes (Gesell et al.
2009, Grothe et al. 2001, Hagel and Facchini 2010, Unterlinner et al. 1999, Ziegler et al. 2006).
Now, high-throughput sequencing technology enables new approaches to biochemical pathway
discovery in the non-model system by providing nucleotide sequence data acquisition at a
previously unparalleled rate. A combination of bioinformatics and high-throughput sequencing
has the potential to shorten natural product pathway discovery if the challenges of interrogating
such large datasets from non-model systems is overcome. We present herein the discovery of
four V. californicum enzymes that catalyze the first six steps from cholesterol to verazine, a
predicted precursor to the steroid alkaloid cyclopamine. We utilize a biosynthetic gene discovery
method founded on correlating metabolite accumulation with RNA-seq generated gene
expression data. By stepwise refactoring of the pathway in Spodoptera frugiperda Sf9 cells, we
eliminate the need to synthesize biosynthetic intermediates for validation of pathway enzyme
activity.
2.5 Results
2.5.1 RNA-seq and de novo transcriptome assembly
Multiplex paired-end sequencing of V. californicum cDNA produced from bulb, flower, leaf, fall
rhizome, spring rhizome, fall root, green shoot, white shoot, and tissue culture samples on two 2
x 50 bp Hi-Seq channels produced over 201 million raw reads which were analyzed and filtered
for artifacts/contaminants. The de novo short read assembly generated 56,994 contigs with a
median length of 323 bp and an N50 of 1,471 bp (refer to Table S1 and Table S2 for Illumina
reads generated per file and transcriptome statistics, respectively). Information on accessing the
raw reads and assembled transcriptome can be found in Data S1. Raw mapped read-counts
were utilized as a metric of relative gene expression. The average contig sequence length
indicates high quality assembly and was sufficient for downstream sequence alignment and
phylogenetic gene tree estimation.
2.5.2 Transcriptome dataset interrogation
To provide annotation, predicted peptide sequences were queried against the Pfam and
Superfamily databases in addition to BLAST searches at NCBI using the non-redundant protein
sequence database. Expression data for each contig was normalized using total reads per
organ type to serve as the dataset for Haystack (http://haystack.mocklerlab.org/ )(Mockler et al.
2007).
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LC-MS/MS determination of the steroid alkaloid profile in the same V. californicum tissues used
for RNA-seq identified a pronounced accumulation of cyclopamine in rhizome, followed by root
and bulb (Figure S1), suggesting that biosynthesis occurs in underground organs of the plant.
Since secondary metabolites are most often synthesized at or near their site of accumulation
(Huang and Kutchan 2000, Nims et al. 2006, Onrubia et al. 2011, Weid et al. 2004), we initially
hypothesized that underground tissues (rhizome, root, and bulb) in Veratrum are biosynthetic for
cyclopamine.
Since ca. 20 times more cyclopamine accumulates in subterranean organs, these tissues were
given a value of 20 for the Haystack input while the above ground organs were designated a
value of 1 in order to create a generalized model for cyclopamine biosynthesis. In our approach,
the LC-MS/MS alkaloid data for Veratrum is the input model used to search the deep
transcriptome experimental dataset of Veratrum, correlating metabolite accumulation and gene
expression data as previously reviewed (Saito et al. 2008). We obtained 3,219 contigs that fit
the 20:1 subterranean organ:aerial organ cyclopamine accumulation model.
In addition to identification of genes exhibiting correlating expression patterns with cyclopamine
accumulation, the protein-coding gene sequences in the Veratrum RNA-seq transcriptome
dataset were classified into putative gene families using PlantTribes 2.0
(http://fgp.bio.psu.edu/tribedb/10_genomes/index.pl) (Wall et al. 2008). This dataset was used
to better define and cluster the Veratrum transcripts that are of most interest to the cyclopamine
pathway. Cytochromes P450 were chosen from the resulting dataset due to the hypothesized
oxidative transformations necessary to convert cholesterol into cyclopamine. The alternative
enzyme class would be 2-oxoglutarate-dependent dioxygenases, if the cytochrome P450
dataset did not yield positive results.
Top candidate genes from the Haystack and tribe clustering analysis with the highest homology
to cytochrome P450 enzymes involved in triterpene and fatty acid hydroxylation/ biosynthesis
were selected for downstream functional characterization (Table S3). Incorporation of nitrogen
into the steroid skeleton is required; therefore, aminotransferases fitting the Haystack model
were also included in the candidate gene list (Table S4). Full-length candidate cDNAs were
expressed in S. frugiperda Sf9 cells using a baculovirus-based expression system allowing for
the accommodation of multi-virus infections. S. frugiperda Sf9 cells provide a facile synthetic
biology platform for the systematic refactoring of plant biosynthetic pathways (Diaz Chavez et al.
2011).

Augustin, Megan, 2015, UMSL, p.29

2.5.3 Cholesterol 22-hydroxylase
The top-scoring candidate cDNAs resulting from interrogation of the V. californicum
transcriptome dataset were systematically and individually introduced, together with
Eschscholzia californica cytochrome P450 reductase (CPR), into S. frugiperda Sf9 insect cells,
which were harvested as previously described and used in enzyme assays with cholesterol as
substrate (Diaz Chavez et al. 2011, Rosco et al. 1997). Most cytochrome P450 enzymes require
the addition of a reductase for heterologous expression. In our hands, differences in enzyme
activity were not dependent on the plant species from which the CPR was derived (Gesell et al.
2009). Cholesterol was chosen as the initial precursor for study based upon existing knowledge
of steroid alkaloid biosynthesis (Cordell 1998, Kaneko et al. 1970b). Related compounds were
also tested to determine enzyme specificity (Table S5). The contig designated 2646, which is
annotated as a steroid C-22 hydroxylase, added a hydroxyl group to the 22-position of
cholesterol exclusively in the R orientation as determined by GC-MS (Figure 1; Figure S2 a;
Figure S3 a). The hydroxylation demonstrated in Figure 1 used extracts of Sf9 cells coexpressing contig 2646 and E. californica CPR as we have discovered their ability to utilize
endogenous Sf9 cholesterol as substrate. One variant of 2646 was identified by RT-PCR having
99.8% identity and catalyzing the same enzymatic reaction. Cytochrome P450 (CYP)
assignments for both homologs are CYP90B27v1 and CYP90B27v2, where version
CYP90B27v1, accession KJ869252, was chosen for subsequent analysis. We have designated
this enzyme cholesterol 22-hydroxylase. CYP90B27 also hydroxylated 26-hydroxycholesterol
(27(25R)-hydroxycholesterol) and 7β-hydroxycholesterol in the 22-position as determined by
enzyme assay, but was unable to hydroxylate the 24-methylsterol campesterol, a metabolite
leading into brassinosteroid biosynthesis (Figure S2 e; Figure S4; Figure S5). CYP90B27
oxidizes the hydroxyl group at the 22-position to a ketone, but only to a low degree (Figure 1).
The identity of the enzymatic product of CYP90B27 acting on cholesterol was confirmed by
comparison to 22(R)-hydroxycholesterol standard. The diastereomers 22(R)- and 22(S)hydroxycholesterol are chromatographically resolved by the GC-MS method used (Figure S6).
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2.5.4 22-Hydroxycholesterol 26-hydroxylase/oxidase
To identify the second enzyme in the pathway, a series of triple infections of S. frugiperda Sf9
cells were carried out that contained CYP90B27 and E. californica CPR, but varied the second
enzyme. Candidates for the second enzyme were the remaining top-scoring candidate cDNAs
resulting from interrogation of the V. californicum transcriptome dataset. Contig 12709, which
annotated as a fatty acid hydroxylase, was found to hydroxylate 22(R)-hydroxycholesterol at the
C-26 position forming 22,26-dihydroxycholesterol by GC-MS (Figure 1; Figure S4). This enzyme
also oxidizes the hydroxyl group at the 26 position creating a highly reactive 22-
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hydroxycholesterol-26-al as detected by LC-MS/MS (Figure S7 a). Four variants were
generated by RT-PCR with identities ranging from 93–99%; all catalyze the same reaction.
Hydroxylation of cholesterol by 12709 was not detected (Figure S3); this enzyme was therefore
designated 22-hydroxycholesterol 26-hydroxylase/oxidase. CYP assignments are CYP94N1v1,
CYP94N1v2, CYP94N2v1, and CYP94N2v2. In figures and subsequent text, CYP94N1 refers to
accession KJ869255 which was chosen as the representative variant for this study. The identity
of 22,26-dihydroxycholesterol produced by action of 12709 on 22(R)-hydroxycholesterol was
ultimately determined using the 22-hydroxylating activity of CYP90B27 to produce 22,26–
dihydroxycholesterol from pure 26-hydroxycholesterol and comparing the mass spectra of the
two enzymatic products (Figure S4).
2.5.5 22-Hydroxycholesterol-26-al transaminase
To identify the third enzyme in the pathway, a series of quadruple infections of S. frugiperda Sf9
cells were carried out that contained CYP90B27, CYP94N1, and E. californica CPR, but varied
the third enzyme. Candidates for the third enzyme were the remaining top-scoring candidate
cDNAs. A γ-aminobutyric acid (GABA) transaminase (contig 12084) was shown to incorporate
nitrogen into the 26-position of 22-hydroxycholesterol-26-al using GABA as an amino group
donor to produce 22-hydroxy-26-aminocholesterol as detected by LC-MS/MS (Figure S8 a).
Three variants were found by RT-PCR, each with over 99% identity and all able to catalyze the
same reaction. Evidence for the structure of 22-hydroxy-26-aminocholesterol was obtained by
high resolution MS (Figure S9). 22-Hydroxy-26-aminocholesterol was not produced in Sf9
enzyme assays that included CYP90B27, CYP90G1 (see below), GABAT1, and CPR but lacked
CYP94N1 (Figure S7 b; orange), indicating that addition of nitrogen to position 26 is likely. This
enzyme was designated 22-hydroxycholesterol-26-al transaminase. In figures and subsequent
text, GABAT1 refers exclusively to accession KJ89263, the variant chosen for subsequent
study.GABAT1 was expressed and purified from E. coli and used in enzyme assays to test
potential co-substrates GABA, L-arginine, and L-glutamine (Figure S10). GABA was the only
accepted amino group donor. Minor peaks in the L-arginine and L-glutamine assays are likely
due to GABA present in E. coli (Dhakal et al. 2012).
2.5.6 22-Hydroxy-26-aminocholesterol 22-oxidase
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To identify the fourth enzyme in the pathway, a series of quintuple infections of S. frugiperda Sf9
cells were carried out that contained CYP90B27, CYP94N1, GABAT1, and E. californica CPR,
but varied the fourth enzyme. Candidates for the fourth enzyme were the remaining top-scoring
candidate cDNAs. Contig 13284 was also annotated as a steroid C-22 hydroxylase, but
hydroxylation at the 22-position of cholesterol was not readily detected. It was, however, able to
oxidize an existing hydroxyl group at position 22 to a much greater degree than CYP90B27 as
shown by GC-MS (Figure 1; Figure S2 b). 13284 oxidizes the 22-hydroxy position of 22(R)hydroxycholesterol to form 22-keto-cholesterol (Figure 1), 22,26-dihydroxycholesterol to form
22-keto-26-hydroxycholesterol (Figure 1; Figure S8 b), and 22-hydroxy-26-aminocholesterol to
form a short lived intermediate that cyclizes
to verazine (Figure 2; Figure S8 c). Four
variants were isolated using RT-PCR, each
having more than 97% identity and all able to
perform the same reaction. CYP designations
for each sequence are: CYP90G1v1,
CYP90G1v2, CYP90G1v3, and CYP90G2. In
figures and subsequent text, CYP90G1 refers
to accession KJ869260 which was selected
for further analysis. The structures of the
enzymatic products 22-keto-cholesterol and
22-keto-26-hydroxycholesterol were
confirmed by NMR spectroscopy (Data S2).
The structure of verazine was supported by
high resolution MS (Figure S9). The enzyme
was subsequently designated 22-hydroxy-26aminocholesterol 22-oxidase. Accession
numbers and designations for all
characterized enzymes can be found in Table
S6.
2.5.7 Biosynthetic pathway to verazine
The substrate specificities determined for
these enzymes suggested a potential
metabolic grid in the metabolism of
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cholesterol. CYP90B27 catalyzes the 22-hydroxylation of cholesterol; this is most likely the first
step in the biosynthesis of steroid alkaloids in V. californicum, confirmed by the inability of
CYP94N1 and CYP90G1 to accept cholesterol as substrate (Figure S3).
To establish the pathway order after 22-hydroxylation of cholesterol, a series of enzyme assays
were carried out using S. frugiperda Sf9 cell extracts containing each individual candidate
enzyme. The order of addition for each enzyme was varied, and products were analyzed by GCMS or LC-MS/MS. The flow chart for both sets of experiments is presented in Figure S11. As
seen in Figure S12 c and e, 22-keto-26-hydroxycholesterol was only produced at detectable
levels by CYP90G1 from 22,26-dihydroxycholesterol. CYP94N1 was unable to hydroxylate 22keto-cholesterol at levels detected by GC-MS. The ability of CYP90G1 to accept 22,26dihydroxycholesterol as substrate and produce 22-keto-26-hydroxycholesterol, along with the
lack of product detection for CYP94N1 incubated with 22-keto-cholesterol, provided evidence
that CYP94N1 acted directly after CYP90B27. This evidence was substantiated with another set
of enzyme assays, beginning with CYP90B27, showing that CYP94N1 produced little product
when provided with 22-keto-cholesterol (using the increased sensitivity of LC-MS/MS for
detection) as seen in Figure S7 b; blue, as compared to the large amount of product produced
when 22,26-dihydroxycholesterol is acted upon by CYP90G1 (Figure S7 a; blue).
22-Hydroxy-26-aminocholesterol was produced in Sf9 cells by CYP90B27, CYP94N1, GABAT1,
and CPR in the presence or absence of CYP90G1 (Figure S8 a; c). GABAT1, therefore, did not
require a 22-ketone moiety on the substrate. When CYP90B27 acted in the presence of
CYP94N1, several side products were detected in addition to 22,26-dihydroxycholesterol
(Figure S7 a; red). These compounds included 22-keto-26-hydroxycholesterol, 22hydroxycholesterol-26-al and two unidentified products. Since an amino group was not added to
the 22-ketone moiety of 22-keto-26-hydroxycholesterol, 22-keto-26-hydroxycholesterol most
likely does not participate in this steroid alkaloid pathway. The short lived and highly reactive 22hydroxycholesterol-26-al must therefore be the substrate of GABAT1. After an amino group is
transferred to the C-26 aldehyde, CYP90G1 oxidizes the C-22-hydroxyl moiety to a ketone, and
cyclization to verazine occurs (Figure 2; Figure S8 c).
Evidence for the short-lived intermediate 22-hydroxycholesterol-26-al was obtained by
dimedone aldehyde trapping (Figure S13). The amino group is added prior to oxidation of the C22 hydroxyl group; therefore, the amino group must be transferred to a C-26 aldehyde. The
structure of the predicted cyclic imine verazine was supported by borohydride reduction of the
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double bond (Figure S14) and exact mass analysis as demonstrated by high resolution MS
(Figure S9).
The biosynthetic pathway proposed herein (Figure 3) is similar to a hypothesized pathway
presented in earlier studies of steroid alkaloids in the genus Veratrum. We found, however, that
22-keto-26-hydroxycholesterol (dormantinone) was not readily accepted as substrate for
GABAT1, as verazine was not formed when supplied this compound (Figure S7 a; purple). In
contrast, verazine was formed when 22-hydroxy-26-amino-cholesterol was supplied to
CYP90G1 (Figure S7 a; green). In further support of our proposed pathway, the biosynthetic
intermediates 22-hydroxy-26-aminocholesterol, 22-keto-26-hydroxycholesterol, and verazine
were detected in V. californicum extracts by LC-MS/MS (Figure S15) and the distribution of
these intermediates followed the same accumulation pattern as cyclopamine (Figure S1). 22,26Dihydroxycholesterol (dormantinol) and verazine have also been previously detected in steroid
alkaloid producing Veratrum species and hypothesized to be intermediates in steroid alkaloid
biosynthesis (Adam et al. 1967, Kaneko et al. 1977).
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2.5.8 Site of steroid alkaloid biosynthesis in V. californicum
A comparison was made between biosynthetic gene expression profiles and cyclopamine
accumulation in V. californicum (Figure 4). A pattern emerged that indicates biosynthetic genes
are most highly expressed in root, bulb, and spring rhizome, while cyclopamine (Figure 4;
Figure S1) is highest in spring- and fall rhizome. The hypothesized intermediates 22-hydroxy26-aminocholesterol, 22-keto-26-hydroxycholesterol, and verazine follow a similar trend with
highest accumulation in root, spring- and fall rhizome (Figure S15). Moreover, the higher level of
cyclopamine in fall rhizome compared to spring rhizome suggests an accumulation of the
steroid alkaloid during rhizome growth in summer (Figure S1). Interestingly, fall rhizome has
significantly more cyclopamine relative to transcript level; the opposite is true for bulb (Figure 4).
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2.6 Discussion
The evolutionary origin of specialized metabolism like that in the Veratrum genus is of particular
interest not only for understanding species divergence but also for the recognition of additional
species containing related compounds with potential therapeutic value. Biochemical analysis of
the Veratrum steroid alkaloid pathway herein alongside a recently proposed biosynthetic
pathway for steroid glycoalkaloids in Solanum lycopersicum (Itkin et al. 2013) suggests
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independent origins of the Solanum steroid alkaloids and the Veratrum steroid alkaloids. In S.
lycopersicum, initial transformations of cholesterol include C-22 hydroxylation followed by C-26
hydroxylation and closure of the E-ring. Oxidation at C-26 and subsequent transamination at
that position occur without the formation of the intermediate verazine. In conjunction with our
results, previous work on steroid alkaloid formation in Veratrum does not support E-ring closure
prior to aldehyde formation and transamination (Kaneko et al. 1970a, Kaneko et al. 1975,
Kaneko et al. 1977, Kaneko et al. 1976). Verazine production requires formation of the F-ring
following transamination prior to E-ring closure. If the pathway was identical to that proposed in
S. lycopersicum, E-ring closure prior to amination would not allow for the formation of verazine.
Oxidation at C-26 by the multifunctional CYP94N1 may be the gateway reaction when
comparing the point of divergence between the two pathways. This oxidation in Veratrum allows
for the immediate addition of nitrogen, leading to F-ring closure and verazine formation. In
contrast, the action of GAME11, the 2-oxoglutarate-dependent dioxygenase in the Solanum
pathway, in conjunction with other unidentified enzymes after C-26 hydroxylation, leads to
closure of the E-ring prior to C-26 oxidation and nitrogen addition. The possibility exists that
multiple steroid alkaloid biosynthetic pathways occur in one or both families and those
respective genes are yet to be discovered, as solanidine-type and verazine-like compounds
have been identified in both members of the Liliaceae and Solanaceae (Cordell 1998).
The independent origin of the two pathways is further corroborated by the phylogenetic
relationship of the enzymes involved. A phylogenetic analysis of select cytochrome P450
enzymes, including several involved in steroid metabolism (Figure 5, Table S7), demonstrates
this distinction. CYP90B27 in V. californicum and CYP72A186 (GAME7), the proposed
cholesterol 22-hydroxylase in S. lycopersicum, are in distinct pan-angiosperm clades suggesting
recruitment from separate P450 subfamilies; likewise for CYP72A208 (26-hydroxylase in S.
lycopersicum, GAME8) and V. californicum CYP94N1. Similarly, CYP88B1 (GAME4), the S.
lycopersicum enzyme that performs oxidation at position 26, falls into a well-supported clade
distinct from the clade containing CYP94N1. The phylogenetic placement of these enzymes
alludes to potential convergent evolution of these genes. The similarity of V. californicum
enzymes CYP90B27 and CYP90G1 with the CYP90B1s, enzymes known to participate in
primary brassinosteroid metabolism, may be indicative of steroid alkaloid biosynthesis evolution,
in part, deriving from the brassinosteroid pathway.
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An in-depth phylogenetic analysis (Figure S16, Table S8) of the steroid modifying genes from V.
californicum and S. lycopersicum alongside homologous cytochrome P450 genes taken from
transcriptome assemblies generated by the 1KP and MonAToL sequencing projects (Data S1)
substantiate the hypothesis of independently derived pathways. Three major cytochrome P450
clades emerge. Both V. californicum CYP90B27 and CYP90G1 are localized in Clade 1. Clade
1 contains a number of ancient gene duplications that show evidence of paralog retention with
expression of multiple copies within species, especially in monocots. In agreement with Figure
5, SlCYP90B1 falls into the same well-supported subclade as these two Veratrum genes with
CYP90B27 being more closely related to SlCYP90B1. Clade 2 contains the S. lycopersicum
genes GAME6, GAME7, and GAME8, but no sampled Veratrum genes. Interestingly, this clade
shows several eudicot gene duplications, most likely genome-specific tandem duplications that
are not observed in the monocot species included in this study. V. californicum CYP94N1 is
found in Clade 3. Clade 3 appears to be the least diverse of the three P450 clades containing
multiple copies of homologs only in a few taxa, potentially related to whole genome duplication
events.
We functionally investigated the relatedness of the V. californicum GABAT1 that incorporates
nitrogen into 22-hydroxycholesterol-26-al and the S. lycopersicum GABA transaminase isozyme
2 involved in steroid alkaloid biosynthesis. These enzymes share 64% identity at the amino acid
level. Due to the similarities of the two pathways, we tested whether S. lycopersicum GABA
transaminase isozyme 2 can incorporate nitrogen into 22-hydroxycholesterol-26-al. We
demonstrated that S. lycopersicum GABA transaminase isozyme 2 was able to convert 22hydroxycholesterol-26-al to 22-hydroxy-26-aminocholesterol and, in conjunction with CYP90G1,
resulting in subsequent cyclization to verazine (Figure S8 d). S. lycopersicum GABA
transaminase isozyme 2 was used as query to BLAST the V. californicum transcriptome; the
best hit was another transaminase, contig 674. 674, designated GABAT2, has 68% identity to S.
lycopersicum GABA transaminase isozyme 2 and 69% identity to V. californicum GABAT1 at
the amino acid level. Despite the sequence homology to both V. californicum GABAT1 and S.
lycopersicum GABA transaminase isozyme 2, GABAT2 was unable to convert 22hydroxycholesterol-26-al to 22-hydroxy-26-aminocholesterol at detectable levels (Figure S17).
Overall, our data indicates that CYP90B27, CYP94N1, CYP90G1, and GABAT1 catalyze the
first six steps of steroid alkaloid biosynthesis in V. californicum to form verazine, a proposed
intermediate of the antineoplastic cyclopamine. We refactored the pathway to verazine in S.
frugiperda Sf9 cells by infections with viruses containing each gene, thereby demonstrating
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gene-product function. Verazine exhibits strong antifungal properties and can serve as a
synthon for the synthesis of bioactive molecules with additional pharmaceutical properties
including liver protection and anti-tumor activities (Gan et al. 1993, Jiang et al. 2005, Kusano et
al. 1987, Zhou 2003). We also demonstrated that the precursor in this pathway is 22(R)hydroxycholesterol rather than 22(S)-hydroxycholesterol, as previously proposed (Kaneko et al.
1977). Our data suggests that dormantinone is not an intermediate in the formation of verazine,
and the amino donor for GABAT1 is GABA rather than L-arginine or L-glutamine (Kaneko et al.
1976).
The candidate gene selection criteria with emphasis on clades that contained only Veratrum
genes fitting the Haystack model increased our rate of gene identification. Of the 3,219 genes
fitting the Haystack model, 9 cytochrome P450 genes were assigned high priority for
biochemical characterization. Seven were tested; 3 catalyzed the first reactions in the verazine
biosynthesis pathway. Likewise, 3 GABATs were prioritized for functional characterization; 1
GABAT was found to participate in the verazine pathway. Based upon the success of this
methodology, we expect continued, facile elucidation of this and other biochemical pathways
from non-model systems.
2.7 Experimental procedures
Plant material and RNA extraction
See Method S1 and Table S9.
Liquid chromatography mass spectrometry (LC-MS/MS) method
Samples were first extracted with either ethanol (see Method S2) for plant tissue or ethyl
acetate for Sf9 cell suspensions and enzymatic assays. Liquid chromatographic separation was
achieved with 10 µl injections on a LC-20AD (Shimadzu) LC system coupled to a 4000 QTRAP
(AB Sciex Instruments) for MS/MS analysis. Separation was achieved using a Phenomenex
Gemini C-18 NX column (150 X 2.00 mm, 5 µm) with a flow rate of 0.5 ml/min and the following
gradient program [solvent A (0.05% formic acid/0.04% ammonium hydroxide (25%) v/v in H 2O;
solvent B (0.05% formic acid/0.04% ammonium hydroxide (25%) v/v in 90% acetonitrile]:
Solvent B was held at 20% for 2 min, then 2-11 min 20-30% B, 11 – 18 min 30-100% B, 18-22
min 100% B, 22-23 min 100-20% B, and held at 20% B for an additional 5 minutes. Program
parameters included a TurboIonSpray ionization source temperature of 500°C and low
resolution for Q1 and Q3 done with MRM (Multiple Reaction Monitoring) scans in the positive
ion mode. Specific ion fragments and parameters can be found in Table S10. In conjunction,
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EMS (Enhanced MS) scan with a mass range of 380 to 425 m/z, and EPI (Enhanced Product
Ion) scans for 398, 417, and 418 m/z were included. Compound identification was determined
by comparison of retention time and fragmentation pattern to the authentic standard
cyclopamine (Infinity Pharmaceuticals) (where applicable). Quantitation was performed by
plotting peak area versus pmol of standard using Analyst 1.5 (Applied Biosystems).
Gas chromatography mass spectrometry (GC-MS) method
Samples were first extracted with either hexane:isopropanol 3:2 followed by hexane only or
ethyl acetate. Dried extracts were derivatized with 40 µl Sylon HTP (Sigma) for 1 hour at 90°C
prior to injection with a 7683B autosampler onto a 7890A gas chromatograph coupled to a
5975C mass spectrometer inert XL MSD with triple-axis detector (Agilent Technologies). Both
full scan and SIM methods were run in the splitless mode with 1 µl injection volume and a flow
rate of 1 ml/min with helium as the carrier gas. Separation was performed on a Zebron ZB-5MSi
column (Phenomenex) with guardian 5M (30 m x 0.25 mm x 0.25 µm) with 5% Polysilarylene 95% Polydimethylsiloxane copolymer composition and 106 relative voltage. The initial
temperature of 240°C was held for 5 minutes and increased to 300°C at a rate of 10°C/min and
held for 25 minutes. The full scan method measured mass from 50 to 800 amu and ions
detected in the SIM mode included: 99.1, 129, 165, 171, 173.1, 187, 261, 314.1, 329.3, 330,
370, 382.3, 417.4, 456.4, 458, 460, 470, 472.3, 486, 546, 560, and 634.
Veratrum californicum metabolite extraction for quantitation by LC-MS/MS
See Method S2.
Transcriptome assembly and determination of relative contig expression
cDNA library construction, Illumina paired-end sequencing, and de novo transcriptome
assembly were performed at the National Center for Genome Resources (Santa Fe, New
Mexico). Please refer Method S3 for transcriptome assembly details.
Transcriptome dataset interrogation using Haystack and Plant Tribes
Identification of genes whose expression pattern correlated with accumulation of cyclopamine
was determined using the Haystack program (Michael et al. 2008, Mockler et al. 2007). The LCMS/MS cyclopamine quantitation data for the different V. californicum tissues was used to
formulate a model based upon the ratio of biosynthetic tissues. 95 % of the total cyclopamine
was found in the subterranean tissues (root, bulb, and rhizome) whereas 5 % was found above
ground (leaf, shoot, and flower). For the input model, each subterranean tissue was given a
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value of 20 and all above ground tissues including the tissue culture samples was designated 1.
Parameters for Haystack were as follows: correlation cut off = 0.7 fold change = 2, p-value =
0.05 and background = 1. Due to the large data input, Haystack analysis was performed on a
UNIX server in-house as opposed to the version available online. Annotation data was then
merged with the gene outputs from each of the models. Subsequent alignments and
phylogenetic analysis were performed using Muscle algorithm (Edgar 2004) and Mega v6.06
(Tamura et al. 2011). See Method S4 for dataset interrogation using PlantTribes and a detailed
description of methods for contig prioritization.
Construction of viral expression vectors
Candidate contigs obtained from Haystack and phylogenetic analysis were subjected to BLAST
searches (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and global alignments to homologous,
experimentally characterized gene sequences with the CLC Main Workbench 6.8, for prediction
of the open reading frame. Where the reading frame appeared incomplete, Rapid Amplification
of cDNA Ends (RACE) was used to obtain the complete coding sequence. V. californicum cDNA
was prepared from root RNA extracts using M-MLV Reverse Transcriptase (Invitrogen)
according to manufacturer’s instructions. All primer sequences and PCR programs can be found
in Table S11 and S12, respectively. Please refer to Method S5 for specific cloning details.
Virus co-transfection, amplification, and protein production
See Method S6 and Table S13.
Extraction of multiple infections for Sf9 in vivo product production
See Method S7.
Enzyme assays
Each cytochrome P450 co-expressed with CPR in S. frugiperda Sf9 cells and GABAT1 was
subjected to individual enzyme assays with the compounds designated in Table S5 including
cholesterol (Sigma Aldrich), 22(R)-hydroxycholesterol (Sigma Aldrich), 26-hydroxycholesterol
[27(25R)-hydroxycholesterol] (Avanti Polar Lipids Inc.), 22(S)-hydroxycholesterol (American
Radiolabeled Chemicals), 24(S)-hydroxycholesterol (American Radiolabeled Chemicals), 4βhydroxycholesterol (Research Plus Inc.), 7β-hydroxycholesterol (Sigma Aldrich), campesterol
(Avanti Polar Lipids Inc.), β-sitosterol (Sigma Aldrich), stigmasterol (Sigma Aldrich), GABA
(Sigma Aldrich), L-arginine (Sigma Aldrich), and L-glutamine (Sigma Aldrich) to determine
substrate specificity. Compounds were prepared to 1 mM stock solutions of 100% DMSO and
diluted with H2O, except for the amino acids, which were prepared as 200 mM stocks in pure
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H2O. For GC-MS analysis, 5 individual assays per substrate were pooled after incubation at
30°C for 2 hours; one assay produced sufficient product for analysis by LC-MS/MS. Assay
conditions were as follows: 80 µl S. frugiperda Sf9 cell suspension (obtained by re-suspension
of 50 ml viral infected culture pellet in 3.5 ml of 100 mM tricine pH 7.4/ 5 mM thioglycolic acid),
60 mM potassium phosphate buffer pH 8, 1.25 mM NADPH, 7.5 µM substrate, and H2O in a
total volume of 200 µl. Controls were performed with no enzyme and S. frugiperda Sf9 cells
expressing an unrelated cytochrome P450 (CYP719A14 cheilanthifoline synthase from
Argemone mexicana), or CPR-only, for each assay.
The initial GABAT1 enzyme assay contained 55 µl S. frugiperda Sf9 cell suspension infected
with CYP90B27, CYP94N1, CYP90G1, and CPR modified baculoviruses (to provide 22hydroxycholesterol-26-al substrate), 40 µl S. frugiperda Sf9 cells expressing GABAT1, 60 mM
potassium phosphate buffer pH 8, 1.5 mM DTT, 100 µM pyridoxal-5-phosphate (PLP), 16 mM
GABA, 500 µM NADPH, and H2O to a total volume of 200 µl. Assay mixes lacking either
enzyme or GABA, and control cytochrome P450 assays were run in parallel and each was
allowed to proceed for 2 hours at 30°C. Samples were extracted twice with 400 µl ethyl acetate.
For determination of the amino group donor, assays were prepared as above for GABAT1 with
the following exceptions. The GABAT1 gene was cloned into the EcoRI/NdeI sites of pET28a
and expressed in E.coli PlusE cells. The GABAT1 protein was purified in the presence of 2
µg/ml PLP using TALON metal affinity resin (Clontech) and PD-10 desalting columns (GE
Healthcare) according to manufacturer’s instructions to obtain purified enzyme. The substrate
22-hydroxycholesterol-26-al was obtained by extracting 2 ml of Sf9 cells expressing CYP90B27,
CYP94N1, and CPR with 2 volumes of ethyl acetate and dried with N2. The dried extract was
resuspended in 400 µl of 10% DMSO. Assays were performed in duplicate and each run with
22-hydroxycholesterol-26-al and either GABA, L-arginine, or L-glutamine alongside CPR only
controls and controls using GABAT1 expressed in Sf9 cells. Samples were then dried under N2,
re-suspended in 50-100 µl 80% methanol, and injected onto LC-MS/MS with conditions
described above. All cytochrome P450 enzyme assays utilized crude S. frugiperda Sf9 protein
extracts that contain endogenous metabolites, including cholesterol.
Assays to clarify order of enzymatic transformations
See Method S8 and Figure S11.
Enzymatic product purification for NMR and High Resolution MS for structure elucidation
See Method S9 and Data S2.
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Dimedone aldehyde trapping
Enzyme assays containing CYP94N1 and 22(R)-hydroxycholesterol as substrate, or CYP90B27
+ CYP94N1 utilizing endogenous cholesterol in S. frugiperda Sf9 cells as substrate, or
CYP90B27 + CYP94N1 and GABAT1, also utilizing endogenous cholesterol in S. frugiperda Sf9
cells as substrate with either 80 µl 10 mg/ml dimedone in 10% DMSO or 80 µl 10% DMSO were
incubated overnight at 30°C. Assays were extracted twice with 2 volumes ethyl acetate and
analyzed by LC-MS/MS. All cytochrome P450 enzymes were co-expressed with CPR.
Sodium borohydride reduction
2 ml S. frugiperda Sf9 cells expressing CYP90B27 + CYP94N1 + GABAT1 + CYP90G1 + CPR
were extracted twice with equal volume ethyl acetate. Extracts were divided equally, dried under
N2, and re-suspended in 50 µl 80% methanol each. One sample was treated with 50 µl 1 M
NaBH4 in 1 M NaOH for 15 minutes. 100 µl H2O were added to both samples, and each
extracted twice with equal volumes of chloroform. Samples were dried under N2, re-suspended
in 50 µl 80% methanol and analyzed by LC-MS/MS as described above. S. frugiperda Sf9 cells
expressing CPR only were run in parallel as control.
Phylogenetic analysis of cytochrome P450 enzymes across species using deep
transcriptome sequence data from 1KP and MonAToL projects
See Method S10 and Table S8.
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Figure S16. Phylogenetic tree of cytochrome P450 enzymes using transcriptome data
from 1KP and MonAToL sequencing projects. The maximum likelihood tree depicting
relationships of P450 genes from across angiosperms and other land plants demonstrates
conservation of ancient diversification within gene families. Both ancient and recent gene
duplications arise within angiosperms with the P450 gene family. Sequences were obtained by
alignment of Veratrum californicum P450 enzymes CYP90B27, CYP90G1, and CYP94N1, and
the S. lycopersicum genes GAME4, GAME 6, GAME 7, and GAME 8 to homologous sequences
found in the 1kP and MonAToL sequencing projects. Refer to Table S8 for species key and
sequence source.
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2.9.2 Supporting tables

Table S1. Sequence reads and length generated for each RNA sample (paired end).
Tissue Used for RNA

Sequence Reads Per File

Average Read Length

Bulb

8,870,015

50

Flower

10,499,190

50

Leaf

8,811,375

50

Fall Rhizome

10,558,614

50

Spring Rhizome

11,237,164

50

Fall Roots

8,026,623

50

Green Shoots

10,021,063

50

White Shoots

10,563,408

50

Tissue Culture Week 1

9,946,944

50

Tissue Culture Week 2

12,413,973

50

Table S2. Transcriptome statistics provided by the NCGR.
Sequences

56994

Bases

41106915

Minimum length

100

Maximum length

16273

N50

1471

B1000*

64.4%
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B2000**

35.9%

*B1000 is the percent of scaffolds greater than 1000 bases and **B2000 is the percent of
scaffolds greater than 2000 bases.
Table S3. Selected top-scoring cytochrome P450 candidate cDNAs for the enzymatic
conversion of cholesterol to cyclopamine.
Gene ID

Putative function

>medp_verca-20110208|2398

similar to CYP71D unknown function*

>medp_verca-20110208|31930

similar to CYP71D unknown function

>medp_verca-20110208|10041

similar to CYP728 taxane 13a-hydroxylase*

>medp_verca-20110208|13942

similar to CYP734 brassinolide C-26 hydroxylase*

>medp_verca-20110208|13284

similar to CYP90B1 steroid C-22 hydroxylase*+

>medp_verca-20110208|18017

similar to CYP90B1 steroid C-22 hydroxylase

>medp_verca-20110208|18580

similar to CYP90B1 steroid C-22 hydroxylase*+

>medp_verca-20110208|2646

similar to CYP90B1 steroid C-22 hydroxylase*

>medp_verca-20110208|32399

similar to CYP90B1 steroid C-22 hydroxylase

>medp_verca-20110208|12709

similar to CYP94D unknown function*

*indicates contigs that were successfully cloned and tested
+contigs are homologs, and exhibited the same function
Table S4. Selected top-scoring transaminases in the steroid alkaloid biosynthetic pathway to
cyclopamine.
Gene ID

Putative function

>medp_verca-20110208|12217

aminotransferase ACS10

>medp_verca-20110208|12084

gamma aminobutyrate transaminase 1, mitochondrial-like*
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>medp_verca-20110208|5285

1-aminocyclopropane-1-carboxylate synthase

>medp_verca-20110208|28717

aminotransferase ACS12-like*

>medp_verca-20110208|15871

histidinol-phosphate aminotransferase, chloroplastic-like*

>medp_verca-20110208|10159

cysteine desulfurase 1

>medp_verca-20110208|1461

methionine S-methyltransferase

*indicates contigs that were successfully cloned and tested.

Table S5. Substrate testing for cytochrome P450 enzymes co-expressed with CPR. Production
of a detectable product is indicated by a (+). CYP90B27 refers to cholesterol 22-hydroxylase,
CYP90G1 refers to 22-hydroxy-26-aminocholesterol 22-oxidase, and CYP94N1 refers to 22hydroxycholesterol 26-hydroxylase/oxidase.
CYP90B27

CYP90G1

CYP94N1

cholesterol

+

-

-

22(R)-hydroxycholesterol

+

+

+

22(S)-hydroxycholesterol

-

-

-

26-hydroxycholesterol

+

-

N/A

22,26-dihydroxycholesterol

N/A

+

N/A

22-keto-cholesterol

N/A

N/A

-

4β-hydroxycholesterol

-

-

-

7β-hydroxycholesterol

+

-

-

24(S)-hydroxycholesterol

-

-

-

campesterol

-

N/A

N/A

β-sitosterol

-

N/A

N/A

stigmasterol

-

N/A

N/A

Table S6. Assigned enzyme names.
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Transcriptome
derived contig

CYP designation

Accession numbers

CYP90B27v1

KJ869252

designations
>medp_verca20110208|2646

Assigned name
based on function

Cholesterol 22hydroxylase

CYP90B27v2

KJ869253

Cholesterol 22hydroxylase
22-

>medp_verca-

CYP94N1v1

20110208|12709

KJ869254

Hydroxycholesterol
26hydroxylase/oxidase
22-

CYP94N1v2

KJ869255

Hydroxycholesterol
26hydroxylase/oxidase
22-

CYP94N2v1

KJ869256

Hydroxycholesterol
26hydroxylase/oxidase
22-

CYP94N2v2

KJ869257

Hydroxycholesterol
26hydroxylase/oxidase

>medp_verca20110208|12084

N/A

KJ869262

22Hydroxycholesterol26-al transaminase
22-

N/A

KJ869263

Hydroxycholesterol26-al transaminase
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22N/A

KJ869264

Hydroxycholesterol26-al transaminase

>medp_verca-

CYP90G1v1

20110208|13284

22-Hydroxy-26KJ869258

aminocholesterol 22oxidase

CYP90G1v2

22-Hydroxy-26KJ869261

aminocholesterol 22oxidase

CYP90G1v3

22-Hydroxy-26KJ869260

aminocholesterol 22oxidase
22-Hydroxy-26-

CYP90G2

KJ869259

aminocholesterol 22oxidase

Table S7. Accession numbers and both putative and determined function for sequences in
cytochrome P450 phylogenetic tree.

Name On Tree

VrCYP90A2

AtCYP90A1

SlCYP90A5

ZeCYP90A11

Species

Accession

Name

Number

Vigna radiata

AF279252

Arabidopsis
thaliana
Solanum
lycopersicum
Zinnia
elegans

AY087526.1

Function
3-Epi-6-deoxocathasterone 23monooxygenase
C-3 oxidation of the early brassinosteroid
intermediates

XM_004240898

Steroid 22-alpha-hydroxylase

AB231153

Steroid 23-alpha-hydroxylase

OsCYP90A3

Oryza sativa

AB206580

Brassinosteroid c-23-hydroxylase

AtCYP90B1

Arabidopsis

AF412114

Steroid 22-alpha-hydroxylase
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thaliana
SlCYP90B1
OsCYP90B2
AtCYP90D1

AtCYP90C1

PtCYP90D1
OsCYP90D2
SmCYP90F1v1

SmCYP90E1

Solanum

Solyc02g085360.

lycopersicum

2.1

Oryza sativa

AB206579.1

Arabidopsis
thaliana
Arabidopsis
thaliana

NM_112223.2

NM_119801

monooxygenase

.1

monooxygenase

Oryza sativa

NM_001048832.1

Steroid 23-alpha-hydroxylase

XM_002968284.1

Unknown

XM_002979568.1

Unknown

Selaginella
moellendorffii
Selaginella
moellendorffii

OsCYP724B1

Oryza sativa

NM_001059582.1

CYP90G1

Veratrum

(13284)

californicum

CYP90B27

Veratrum

(2646)

californicum

StCYP716A13

3-Epi-6-deoxocathasterone 23-

trichocarpa

2.1

MtCYP716A12

monooxygenase

3-Epi-6-deoxocathasterone 23-

lycopersicum

AaCYP716A14

3-Epi-6-deoxocathasterone 23-

Potri.001G200100

Solyc02g093540.

MtCYP718A8

Steroid 22-alpha-hydroxylase

Populus

Solanum

SlCYP724B1

Steroid 22-alpha-hydroxylase

Medicago
truncatula
Artemisia
annua
Medicago
truncatula
Solanum
tuberosum

SlCYP88B1

Solanum

(GAME4)

lycopersicum

ZmCYP88A1

Zea mays

KJ869260

Unknown
Steroid 22-alpha-hydroxylase
22-Hydroxy-26-aminocholesterol 22oxidase

KJ869252

Cholesterol 22-hydroxylase

XM_003617407

Taxane 13-alpha-hydroxylase

DQ363134

Taxadiene 5-alpha-hydroxylase

DQ335781

3-Epi-6-deoxocathasterone 23monooxygenase

XM_006338067

Unknown

XM_004251512.1

Steroid 26-oxidase

NM_001112116.1

Early step in gibberellin biosynthesis

Augustin, Megan, 2015, UMSL, p.69

LjCYP88D4

MtCYP88D3

GuCYP88D6

AtCYP710A1
VsCYP94A1
AtCYP94B3

PpCYP94C

SmCYP94J1

SlCYP94A1

NtCYP94A4

Lotus

AB433177

Beta-amyrin 11-oxidase

AB433176.1

Unknown

AB433179.1

Beta-amyrin 11-oxidase

NM_129002.2

C-22 sterol desaturase

AF030260

Fatty acid omega-hydroxylase

BT015841.1

Converts JA-Ile to 12-hydroxy-JA-Ile

XM_001763154.1

Unknown

XM_002979639.1

Medium chain fatty acid hydroxylase

Solanum

Solyc09g066150.

Cytochrome P450-dependent fatty acid

lycopersicum

1.1

hydroxylase

AF092915

Fatty acid hydroxylase

japonicus
Medicago
truncatula
Glycyrrhiza
uralensis
Arabidopsis
thaliana
Vicia sativa
Arabidopsis
thaliana
Physcomitrell
a patens
Selaginella
moellendorffii

Nicotiana
tabacum

CYP94N1

Veratrum

(12709)

californicum

PCYP86A22

AtCYP86A1
OsCYP714B1
OsCYP714AD
1
SlCYP734A7

AtCYP734A1
OsCYP74A3

Petunia x

KJ869255

22-Hydroxycholesterol 26hydroxylase/oxidase

DQ099538.1

Fatty acid omega-hydroxylase

NM_125276.2

Fatty acid omega-hydroxylase

Oryza sativa

NM_001067187.1

Gibberellin 13-oxidase

Oryza sativa

AY987039.1

hybrida
Arabidopsis
thaliana

Solanum
lycopersicum
Arabidopsis
thaliana
Oryza sativa

NM_001247011

NM_128228
NM_001052842.1

16-Alpha 17-epoxidation on non-13hydroxylated gibberellins
Castasterone 26-hydroxylase
Steroid 26-hydroxylase; 26-hydroxylase
for brassinolide and castasterone
Converts 13-hydroperoxylinolenic acid to
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12,13-epoxylinolenic acid
OsCYP734A2

Oryza sativa

SlCYP72A208

Solanum

(GAME8b)

lycopersicum

AB488666.1

C-26 oxidation of brassinosteroids

NM_001247565.1

22-Hydroxycholesterol 26-hydroxylase

U35226.3

Unknown

XM_004243590.1

Steroidal alkaloid biosynthesis

L10081

Secologanin synthase

AB558152

Beta-amyrin oxidase

DQ335783.1

Unknown

XM_006348844

Unknown

XM_004244225.1

Putative cholesterol 22-hydroxylase

DQ350355.1

Unknown

NM_101566

Brassinosteroid inactivation

Nicotiana
NpCYP72A2

plumbaginifol
ia

SlCYP72A188

Solanum

(GAME6)

lycopersicum

CrCYP72A1

GuCYP72A154

MtCYP72A59

StCYP72A56

Catharanthus
roseus
Glycyrrhiza
uralensis
Medicago
truncatula
Solanum
tuberosum

SlCYP72A186

Solanum

(GAME7)

lycopersicum

NtCYP72A57

AtCYP72C1

AsCYP51H10

MeCYP71E7

TaCYP71F1

CrCYP71BJ1

LsCYP71BL2

Nicotiana
tabacum
Arabidopsis
thaliana
Avena
strigosa
Manihot
esculenta
Triticum
aestivum
Catharanthus
roseus
Lactuca
sativa

DQ680852.1

Beta-amyrin 12,13 epoxidase 16hydroxylase

AY217351

Unknown

AB036772

Ferulate 5-hydroxylase

HQ901597.1

HQ439599.1

Tabersonine/lochnericine 19hydroxylase
Costunolide synthase

Augustin, Megan, 2015, UMSL, p.71

ZmCYP71C1
PCYP75A1

SlCYP85A1
OsCYP76M7
SmCYP76AH1

Zea mays
Petunia x
hybrida
Solanum
lycopersicum
Oryza sativa
Salvia
miltiorrhiza

SaCYP76F37v

Santalum

1

album

PsCYP720B4

Picea
sitchensis

NM_001175287.1

3-Hydroxyindolin-2-one monooxygenase

DQ352142.1

Flavonoid 3',5'-hydroxylase

NM_001247334.1

6-Deoxocastasterone oxidase

AK105913.1

Ent-cassadiene c-11α-hydroxylase

JX422213.1

Ferruginol synthase

KC533717.1

Bergamotene oxidase
Diterpene oxidation to form the diterpene

HM245403.1

resin acids isopimaric acid and abietic
acid

Table S8. Species key and source for sequences in P450 phylogenetic tree using deep
transcriptome sequence data from 1KP and MonAToL projects (Al-Mssallem et al. 2013, D'Hont
et al. 2012).
Species

Source

Zinnia elegans

Genbank (Table S7)

Nicotiana plumbaginifolia

Genbank (Table S7)

Nicotiana tabacum

Genbank (Table S7)

Vigna radiata

Genbank (Table S7)

Glycyrrhiza uralensis

Genbank (Table S7)

Vicia sativa

Genbank (Table S7)

Artemisia annua

Genbank (Table S7)

Arabidopsis thaliana

Genbank (Table S7)

Medicago truncatula

Genbank (Table S7)

Oryza sativa

Genbank (Table S7)

Physcomitrella patens

Genbank (Table S7)

Populus trichopoda

Genbank (Table S7)

Lotus japonicus

Genbank (Table S7)

Selaginella moellendorffii

Genbank (Table S7)
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Solanum lycopersicum

Genbank (Table S7)

Solanum tuberosum

Genbank (Table S7)

Borya sphaerocephala

1KP

Chlorogalum pomeridianum

1KP

Curculigo sp.

1KP

Cyanastrum cordifolium

1KP

Eriospermum lancifolia

1KP

Freycinetia multiflora

1KP

Goodyera pubescens

1KP

Helonia bullata

1KP

Hesperaloe parviflora

1KP

Johnsonia pubescens

1KP

Maianthemum canadense

1KP

Nolina atopocarpa

1KP

Oncidium spacelatum

1KP

Platanthera clavellata

1KP

Ruscus sp.

1KP

Sansevieria trifasciata

1KP

Xeronema callistemon

1KP

Xerophyllum asphodeloides

1KP

Xerophyta villosa

1KP

Yucca brevifolia

1KP

Yucca filamentosa

1KP

Amborella trichopoda

Musa acuminata
Nelumbo nucifera
Phoenix dactylifera

Amobrella Genome
Project
Cirad (D'Hont et al.
2012)
GB: GCA_000365185.2
JCGR (Al-Mssallem et
al. 2013)

Acorus americana

MonAToL

Anemarrhena asphodeloides

MonAToL

Aphyllanthes monspeliensis

MonAToL
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Asparagus asparagoides

MonAToL

Behnia reticulata

MonAToL

Cypripedium acaule

MonAToL

Doryanthes excelsa

MonAToL

Hemiphylacus alatostylus

MonAToL

Ixiolirion sp.

MonAToL

Lanaria larata

MonAToL

Lilium superbum

MonAToL

Paphiopedilum callosum

MonAToL

Phragmidpedium lindleyannum

MonAToL

Hosta venusta

Chlorophytum rhizopendulum

MonAToL; GB:
SRX116252
MonAToL; GB:
SRX116253

Aquilegia coerulea

Phytozome

Arabidopsis thaliana

Phytozome

Carica papya

Phytozome

Fragaria vesca

Phytozome

Glycine max

Phytozome

Medicago truncatula

Phytozome

Mimulus guttatus

Phytozome

Oryza sativa

Phytozome

Populus trichopoda

Phytozome

Selaginella moellendorffii

Phytozome

Solanum lycopersicum

Phytozome

Solanum tuberosum

Phytozome

Sorghum bicolor

Phytozome

Theobroma cacao

Phytozome

Vitis vinifera

Phytozome

Veratrum californicum

This Study

Table S9. LS/MS rooting medium was prepared with the following concentrations and brought
to a final pH of 5.75.
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Macronutrients

Supplier

Final Concentration (mg/l)

NH4NO3

Phytotechnology laboratories

1650

KNO3

Sigma

1900

MgSO4 x 7H2O

Sigma

370

KH2PO4

Sigma

170

CaCl2 x 2H2O

Sigma

440

Na2EDTA x 2H2O

Sigma

37.3

FeSO4 x 7H2O

Sigma

27.8

H3BO3

Sigma

6.2

MnSO4 x H2O

Phytotechnology laboratories

16.9

ZnSO4 x 7H2O

Sigma

8.6

KI

Sigma

0.83

Na2MoO4 x 2H2O

Phytotechnology laboratories

0.25

CuSO4 x 5H2O

Sigma

0.025

CoCl2 x 6H2O

Sigma

0.025

Thiamine HCl

Sigma

0.1

Nicotinic acid

Sigma

0.5

Pyroxidine HCl

Sigma

0.5

Myo-inositol

Sigma

100

Sucrose

Phytotechnology laboratories

30000

1-Naphthaleneacetic acid

Phytotechnology laboratories

0.5

Gelzan

Phytotechnology laboratories

3000

Iron

Micronutrients

Vitamines

Other

Table S10. LC-MS/MS Q-TRAP 4000 method parameters.

Cyclopamine

Declustering

Collision

Potential (V)

Energy (V)

100

120

40

100

120

40

Q1 Mass

Q3 Mass

Dwell (msec)

412

321

412

394
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22-Keto-26hydroxycholesterol

22-Hydroxy-26aminocholesterol

Verazine

417

271

100

70

30

417

253

100

70

30

418

400

100

70

30

418

382

100

70

30

398

253

100

70

60

398

159

100

70

60

Table S11. Primer sequences.
Number

Primer Position and Application

5’ – 3’ Sequence

1

5’ UTR outer for 2646

CAAGTCGTGATTGATGGCTTTAGAAGGCA

2

5’ UTR inner for 2646

TGGATCTCTGAAGCCATGAATCGCTAGTA

3

3’ UTR outer for 2646

TCCTATAACCATTTATTTCTCGTAACC

4

3’ UTR inner for 2646

ATGCAGAGAGCAATATTACAACCCAA

5’ gene specific primer (GSP)
5

used to amplify 2646 and
introduce NotI RS

6

3’ used to amplify 2646 and

TGAGCGGCCGCATGGCGATGGAGCTCTTATTG
TTG
TGAGGATCCTTAGTCTCCGAGGGGGCGAACTT

introduce BamHI RS

7

5’ UTR for 13284

AGAAAGAAAGAGAGAGAGATGACTCCA

8

3’ UTR for 13284

TAGAGAAAGACTGCTTGAATTTTTCAGGCAA

5’ used to amplify 13284 and

GGGCTGCAGATGACTCCACTAGTTGTTCTCTT

introduce PstI RS

C

3’ used to amplify 13284 and

GGGTCTAGATTATTGGAGGAGCGAAAGCCG

9

10

11

12

introduce XbaI RS
5’ used to amplify 12084 and

GGGAGATCTATGGGATCCACTGAGGCGCCTGT

introduce BglII RS

ATC

3’ used to amplify 12084 and

GGGGAATTCTTAAGTTGCGGTATTCTGAGACT

introduce EcoRI RS

GG
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13

5’ outer RACE for 12709

GCACTGGAGCACGAGGACACTGA

14

5’ inner RACE for 12709

GGACACTGACATGGACTGAAGGAGTA

Outer gene specific internal

TGGTCCACCACGTGCGGCCGCGACGAGA

15

16

17

18

19

20

21

22

reverse for 12709 5’ RACE
Inner Gene specific internal

GAACCAGGTGAGCGCCGAGGGGGTGGT

reverse for 12709 5’ RACE
5’ used to amplify 12709 and

GGGAGATCTATGGATCTACCCTCCGCCTC

introduce BglII RS
3’ used to amplify 12709 and

GGGGAATTCCTAACACCCTCTCTTCCTCTCCTT

introduce EcoRI RS

G

5’ used to amplify tomato GABAT2

CACACTGCAGATGGCCAAGACTAATGGATTTAT

and introduce PstI RS

G

3’ used to amplify tomato GABAT2

CACATCTAGATTACTTCTTCTGAGACTTTAATTC

and introduce XbaI RS

TTCCA

5’ used to amplify 674 and

CACACTGCAGATGTTCTCAAGGCAAGCTACAG

introduce PstI RS
3’ used to amplify 674 and

CACATCTAGACTACTTCTGCTTCTGAGACTTGA

introduce XbaI RS

GCT

5’ used to amplify 12084 for
23

insertion into pET28a and

TTTCATATGGGATCCACTGAGGCGCCTGTAT

introduce NdeI RS

24

3’ used to amplify 12084 for

GGGGAATTCTTAAGTTGCGGTATTCTGAGACT

insertion into pET28a and

GGAGCT

introduce EcoRI RS

Table S12. PCR Parameters.
2646 for TOPO cloning, VC2646 for pVL1392

98°C for 30 sec, then 35 cycles of 98°C for 10

cloning, VC12709 for pVL1392 cloning,

sec, 60°C for 30 sec, 72°C for 1 min 30 sec,

VC13284 TOPO cloning

and a final 10 min extension at 72°C
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12709 5’ RACE

98°C for 30 sec, then 35 cycles of 98°C for 10
sec, 65°C for 30 sec, 72°C for 1 min and a
final 10 min extension at 72°C

13284 for pVL1392 cloning

98°C for 30 sec, then 35 cycles of 98°C for 10
sec, 63°C for 30 sec, 72°C for 1 min 25 sec,
and a final 10 min extension at 72°C

12084 for pVL1392 cloning

98°C for 30 sec, then 35 cycles of 98°C for 10
sec, 60°C for 30 sec, 72°C for 1 min, and a
final 10 min extension at 72°C

Tomato GABAT and 674 for pVL1392 cloning

98°C for 30 sec, then 35 cycles of 98°C for 10
sec, 62°C for 30 sec, 72°C for 45 sec, and a
final 10 min extension at 72°C

12084 for pET28a cloning

98°C for 30 sec, then 35 cycles of 98°C for 10
sec, 63°C for 30 sec, 72°C for 2 min, and a
final 10 min extension at 72°C

Table S13. Viral combinations for in vivo production of metabolites in S. frugiperda Sf9 cells.
Combination

Viruses

Combination 1

CYP90B27, CPR

Combination 2

CYP94N1, CPR

Combination 3

CYP90G1, CPR

Combination 4

CYP90B27, CYP94N1, CPR

Combination 5

CYP90B27, CYP90G1, CPR

Combination 6

CYP90B27, CYP94N1, CYP90G1, CPR

Combination 7

Combination 8

CYP90B27, CYP94N1, CYP90G1, GABAT1,
CPR
CYP90B27, CYP94N1, GABAT1, CPR
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Combination 9

Combination 10

CYP90B27, CYP94N1, CYP90G1, GABAT2,
CPR
CYP90B27, CYP94N1, CYP90G1, S.
lycopersicum GABAT2, CPR

2.9.3 Supporting data
Data S1. Data access for sequence information.
Illumina reads and assembled transcriptome retrieval of Veratrum californicum,
Narcissus sp. aff. pseudonarcissus, and Colchicum autumnale.
Each species was assembled by the NCGR and the raw reads, assembled transcriptome, and
readme files can be found at: http://www.medplantrnaseq.org/.
Data access for 1KP and MonATol Projects.
Data for the 1KP can be accessed at https://sites.google.com/a/ualberta.ca/onekp/
Data for the MonATol project is currently unpublished and access to the sequence information
was courtesy of James H. Leebens-Mack (jleebensmack@plantbio.uga.edu). All sequences and
alignments used in this analysis are deposited in Dryad: DOI: doi:10.5061/dryad.n9s7q.
Data S2. NMR designations for 22-keto-cholesterol and 22-keto-26-hydroxycholesterol in
MeOD.
22-keto-cholesterol. 1H NMR (600 MHz, CD3OD):  5.34 (m, 1H, H-6), 3.40 (m, 1H, H-3), 2.522.62 (m, 2H, H-20, H-23), 2.45 (m, 1H, H-23), 2.23 (m, 1H, H-4), 1.95-2.07 (m, 2H, H-7, H-12),
1.88 (dt, J = 13.0, 3.5 Hz, 1H, H-1), 1.78 (m, 1H, H-2), 1.45-1.67 (m, 8H, H-2, H-7, H-11, H-15,
H-16, H-17, H-25), 1.41 (m, 1H, H-24), 1.31 (m, 1H, H-12), 1.19 (m, 1H, H-16), 1.10 (d, J = 7.0
Hz, 3H, H-21), 1.04-1.09 (m, 2H, H-1, H-14), 1.03 (s, 3H, H-19), 0.98 (td, J = 11.0, 5.0 Hz, 1H,
H-9), 0.90 (m, 6H, H-26, H-27), 0.76 (s, 3H, H-18); 13C NMR (150 MHz, CD3OD):  217.8 (C22), 141.9 (C-5), 122.1 (C-6), 72.1 (C-3), 57.3 (C-14), 53.6 (C-17), 51.4 (C-9), 50.2 (C-20), 43.4
(C-13), 42.6 (C-4), 40.8 (C-12), 40.4 (C-23), 38.3 (C-1), 37.7 (C-10), 36.8 (C-8), 33.1 (C-24),
32.7 (C-7), 31.8 (C-2), 28.6 (C-25), 28.2 (C-16), 25.8 (C-15), 22.5 (C-27), 22.0 (C-11), 19.6 (C19), 16.7 (C-21), 13.2 (C-26), 12.2 (C-18).

Augustin, Megan, 2015, UMSL, p.79

22-keto-26-hydroxycholesterol. 1H NMR (600 MHz, CD3OD):  5.34 (br d, J = 5.1 Hz, 1H, H-6),
3.30-3.42 (m, 3H, H-3, H-26), 2.58-2.66 (m, 2H, H-20, H-23), 2.46 (ddd, J = 17.6, 9.2, 5.9 Hz,
1H, H-23), 2.22 (m, 2H, H-4), 1.94-2.03 (m, 2H, H-7, H-12), 1.88 (dt, J = 13.6, 13.3 Hz, 1H, H1), 1.79 (m, 1H, H-2), 1.44-1.70 (m, 10H, H-2, H-7, H-8, H-11, H-15, H-16, H-17, H-24, H-25),
1.30-1.34 (m, 2H, H-12, H-24), 1.21 (m, 1H, H-16), 1.15 (m, 1H, H-15), 1.11 (d, J = 7.0 Hz, 3H,
H-21), 1.04-1.10 (m, 2H, H-1, H-14), 1.03 (s, 3H, H-19), 0.98 (td, J = 11.2, 5.0 Hz, 1H, H-9),
0.91 (d, J = 6.6 Hz, 3H, H-27), 0.76 (s, 3H, H-18); 13C NMR (150 MHz, CD3OD):  217.0 (C-22),
141.2 (C-5), 122.1 (C-6), 72.1 (C-3), 67.7 (C-27), 57.1 (C-14), 53.3 (C-17), 51.3 (C-9), 50.2 (C20), 43.2 (C-13), 42.7 (C-4), 40.6 (C-12), 40.1 (C-23), 38.3 (C-1), 37.4 (C-10), 35.9 (C-25), 32.7
(C-7), 32.5 (C-8), 31.9 (C-2), 28.1 (C-16), 27.4 (C-24), 25.4 (C-15), 21.8 (C-11), 19.6 (C-19),
16.7 (C-21), 16.6 (C-27), 12.0 (C-18).
2.9.4 Supporting methods
Method S1. Plant material and RNA extraction.
Veratrum californicum plant material was obtained from wild populations in northern Utah.
Tissue culture was initiated from wild collected seed and grown in the dark at 24°C on a
combination of Linsmaier and Skoog vitamins (Linsmaier E.M. 1965) and Murashige and Skoog
media(Murashige 1962) supplemented with 0.5 mg/l 1-naphthaleneacetic acid (Sigma). Refer to
Table S9 for detailed media components. RNA extraction for each tissue (bulb, flower, leaf, fall
rhizome, spring rhizome, fall root, green shoot, white shoot, and tissue culture samples) was
performed as previously described (Johnson et al. 2012) (protocol 13). RNA quantity and
integrity were evaluated with a NanoDrop 2000 (Thermo Scientific) and a Bioanalyzer 2100
(Agilent Technologies) prior to cDNA library preparation.
Method S2. Veratrum californicum metabolite extraction for quantitation by LC-MS/MS.
Extracts were prepared by grinding frozen plant tissue in liquid nitrogen followed by 5 minutes of
vortexing in 70% ethanol added in a 200 µl to 100 mg w/v ratio. Samples were subject to
centrifugation for 10 minutes (14,000 X g) at room temperature and the supernatant filtered
through a 0.2 µm PTFE membrane (Millipore) prior to injection. Extracts were diluted 10-10,000
fold with 70% ethanol, depending on alkaloid concentration, prior to LC-MS/MS analysis (refer
to LC-MS/MS protocol in Experimental Procedures).
Method S3. Transcriptome assembly and determination of relative contig expression.
cDNA library construction, Illumina paired-end sequencing, and de novo transcriptome
assembly for Veratrum californicum were performed at the National Center for Genome
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Resources (Santa Fe, New Mexico). For the transcriptome assembly, 50 bp paired-end Illumina
reads for each tissue were first examined for gross abnormalities and poor sequence quality
and trimmed with the FASTX Toolkit. (http://hannonlab.cshl.edu/fastx_toolkit). Quality control
was as previously described (Kilgore et al. 2014).The reads were 5′ and 3′ quality trimmed using
a Phred score of 15 to eliminate noisy reads. Subsequently, short contig assembly was
performed using the de Bruijn graph-based assembler ABySS (Assembly by Short Sequences)
several times with varying k-mer lengths to generate 20 sets of synthetic ESTs (Expressed
Sequence Tags) with lengths between 100 – 500 base pairs (Birol et al. 2009, Simpson et al.
2009). ABySS scaffolder was used to scaffold the synthetic ESTs and GapCloser from
SOAPdenovo (Short Oligonucleotide Analysis Package) to close the NNN gap spacers (Li et al.
2010). Lastly, the assembly was completed by combining the obtained scaffolds using MIRA
(Mimicking Intelligent Read Assembly) in the EST assembly mode (Chevreux 2005). Post
processing included translational predictions for each contig using ESTSCAN (Iseli et al. 1999,
Lottaz et al. 2003), protein product motif annotation written to GFF3 files (General Feature
Format), and determination of expression data by alignment analysis of the trimmed reads to
the assembled contigs using BWA (Burrows-Wheeler Aligner) (Li and Durbin 2009). To further
enable comparison of gene expression between various tissues, the number of reads aligned to
each contig was normalized by dividing by the total number of reads from the respective tissue
sample. Functional annotations to each predicted protein sequence were obtained using Pfam
(Punta et al. 2012), Superfamily (Gough et al. 2001), and Uniprot (UniProt 2013).
Method S4. Transcriptome dataset interrogation using Haystack and PlantTribes.
Haystack (http://haystack.mocklerlab.org/) input parameters included a value of 20 for fall root,
fall rhizome, spring rhizome and bulb and a value of 1 for leaf, flower, white shoot, green shoot,
and tissue culture 1- and 2 weeks after transfer to new media. A correlation cutoff value of 0.7
was used instead of the default of 0.8 to avoid missing true positives.
Gene family circumscriptions in PlantTribes were calculated using the similarity-based clustering
of gene models from Arabidopsis thaliana (v. 7), Carica papaya (v.1), Populus trichocarpa (v. 1),
Medicago truncatula (v. 1), Oryza sativa (v. 5), Sorghum bicolor (v. 1), Selaginella moellendorffii
(v. 1), Physcomitrella patens (v. 1), and Chlamydomonas reinhardtii (v. 1) genome annotations
using TribeMCL (Enright et al. 2003, Enright et al. 2002). Translated transcript assemblies for
Veratrum californicum, Narcissus sp. aff. pseudonarcissus (daffodil), and Colchicum autumnale
(autumn crocus) were sorted into the resulting gene family clusters using BLAST followed by
multiple sequence alignment and gene tree estimation. In addition to this MCL (Markov CLuster
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algorithm) clustering approach, we developed a complete minimal representative dataset from
all available plant species of cytochrome P450 genes relevant to alkaloid biosynthesis to identify
candidate cytochromes P450.

Multiple sequence alignment and phylogenetic tree estimation were done on these relevant
tribes and gene families using the MAFFT (Multiple Alignment using Fast Fourier Transform)
alignment software (Katoh et al. 2009) and RAxML (Randomized Axelerated Maximum
Likelihood) for maximum likelihood tree generation (Stamatakis 2006).

The RNA-seq transcriptome assembly sequences from C. autumnale and Narcissus were
included in the tribe clustering steps (Supporting Data S1). These two species are also lillioid
monocots but do not produce cyclopamine (but instead make the unrelated alkaloids colchicine
and galanthamine, respectively), C. autumnale and Narcissus sequences were included in order
to facilitate identification of tribe clusters that only contain Veratrum californicum genes, which
were then assigned a higher priority for biochemical validation.

Selection criteria were established to score and sort the resulting clades, positive criteria were
given a +1 each while penalizations were scored as a -1 each. A given clade was scored on the
percentage of clade members that significantly co-localized with cyclopamine (e.g. present in
the Haystack output dataset). Clades that did not contain any genes that fit the Haystack model
were penalized. Clades containing genes that were not significantly co-localized with the
alkaloid were penalized. Lastly, clades that contain genes from species that do not produce
cyclopamine incurred a score penalty and were not chosen for initial biochemical
characterization. These criteria were combined to score and rank the clades that contain
Haystack output gene members to identify the clade(s) with the highest likelihood of containing
genes that function in the steroid alkaloid biosynthesis pathway.

Method S5. Construction of viral expression vectors.
Candidate contigs obtained from Haystack analysis were subjected to BLAST searches
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and global alignments to homologous, experimentally
characterized gene sequences with the CLC Main Workbench 6.8, for prediction of the open
reading frame. Where the reading frame appeared incomplete, Rapid Amplification of cDNA
Ends (RACE) was used to obtain the complete coding sequence. Veratrum californicum cDNA
was prepared from root RNA extracts using M-MLV Reverse Transcriptase (Invitrogen)
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according to manufacturer’s instructions. All primer sequences and PCR programs can be found
in Tables S11 and S12, respectively.
The cDNAs encoding CYP90B27 (accession numbers KJ869252, KJ869253), CYP90G1
(accession numbers KJ869258-KJ869261), GABAT1 (accession numbers KJ869262KJ869264) and γ-aminobutyrate transaminase 2 (GABAT2) (accession number KJ869265) were
determined to be full length. CYP90B27 and CYP90G1 were amplified by Polymerase Chain
Reaction (PCR) from cDNA with Phusion DNA polymerase (New England Biolabs) using
primers 1-4 and 7-8, respectively, and initially ligated into the pCR-Blunt II-TOPO vector
(Invitrogen). Two rounds of amplification were required for CYP90B27 by nested PCR.
Subsequently, CYP90B27 was amplified from pCR-Blunt II-TOPO with primers 5 and 6
introducing NotI/BamHI restriction sites into the PCR products at the 5’ and 3’ ends of the open
reading frame. The amplified product and pVL1392 Baculovirus transfer vector (BD
Biosciences) were digested with NotI/BamHI and ligated together using Rapid Ligase
(Promega). Ligated constructs were transformed into E. coli DH5α competent cells. CYP90G1
was amplified with primers 9 and 10, introducing PstI/XbaI restriction sites at the 5’ and 3’ end of
the open reading frame. The amplified product, along with pVL1392, was digested with
PstI/XbaI and subject to ligation and transformation.
GABAT1 and GABAT2 were directly amplified from cDNA using primers 11, 12 incorporating
BglII/EcoRI restriction sites at the 5’ and 3’ end of the open reading frame and 21, 22,
incorporating PstI/XbaI restriction sites at the 5’ and 3’ end of the open reading frame,
respectively. GABAT1 and pVL1392 were subject to restriction digest with BglII/EcoRI
preceding ligation and transformation. GABAT2 was digested with XbaI/PstI, preceding ligation
and transformation.
RACE was required to determine the 5’ sequence of CYP94N1 gene (accession numbers
KJ869254-KJ869257). RACE ready cDNA was prepared using the GeneRacer Kit (Invitrogen)
according to manufacturer’s instructions using V. californicum root RNA. Primers 13 and 15
were used for PCR (round 1), followed by amplification using primers 14 and 16 (round 2).
Resulting RACE fragments were cloned into PCR-Blunt II-TOPO. The full-length gene was
directly amplified from V. californicum root cDNA with primers 17 and 18, incorporating
BglII/EcoRI restriction sites at the 5’ and 3’ end of the open reading frame. The amplified
product was digested with Bglll/EcoRI and ligated into pVL1392 digested with the same
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enzymes. Each characterized V. californicum contig and subsequent enzyme designation can
be found in Table S6.
The cDNA encoding GABA transaminase isozyme 2 from Solanum lycopersicum (tomato
GABAT2) implicated in steroid alkaloid biosynthesis (accession number AY240230) was
isolated from S. lycopersicum using the Qiagen RNA-easy kit for RNA extraction followed by
cDNA synthesis as described above. Tomato GABAT2 was amplified by PCR using Primers 19
and 20, incorporating PstI/XbaI sites at the 5’ and 3’ end of the open reading frame. The
amplified product and pVL1392 were subject to restriction digest with PstI/XbaI and ligated
together, preceding transformation.
Method S6. Virus co-transfection, amplification, and protein production.
Each pVL1392 expression construct was independently co-transfected with the Baculogold
Linearized Baculovirus (BD Biosciences) into S. frugiperda Sf9 cells according to
manufacturer’s instructions. Sf9 cells were maintained as previously described (Gesell et al.
2011). Virus amplification and protein production proceeded as previously described (Gesell et
al. 2009). Each cytochrome P450 virus construct was co-expressed with virus containing E.
californica cytochrome P450 reductase (CPR) while the GABAT1 was produced by single
infection. Sf9 cell cultures were also infected with several constructs in parallel. Combinations of
each virus used in multiple infections can be found in Table S13. Equal volumes for each virus
were used in the multiple infections and adjusted to a total viral volume of 2.5 ml.
Method S7. Extraction of multiple infections for Sf9 in vivo product production.
Baculovirus infections were carried out for production of each enzymatic product in S. frugiperda
Sf9 cells and collected as stated in Method S6. 1 ml each of Sf9 cells expressing the various
combinations of virus were extracted with 2 volumes of ethyl acetate by vortexing (1 min),
centrifugation (16,000 x g; 2 min), and were taken to dryness under N2. Samples were either
derivatized with 40 µl of Sylon HTP and injected onto the GC-MS using the protocol stated in
Experimental Procedures or were re-suspended in 50 µl of 80% methanol and analyzed by
LC/MS-MS according to the protocol in Experimental Procedures.
Method S8. Assays to clarify order of enzymatic transformations.
Assay for GC-MS: Cytochrome P450 enzyme assay conditions were identical to those stated
above using S. frugiperda Sf9 cell suspensions with the following modifications. First, 12 assays
each containing CYP90G1 + CPR, CYP94N1 + CPR, or control cytochrome P450 + CPR and
each with pure 22(R)-hydroxycholesterol were allowed to incubate overnight at 30°C. Like
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assays were pooled, extracted 3 times with 2 volumes ethyl acetate, dried under N2, and resuspended in 180 µl of 25% DMSO. Extracts containing the enzymatic product of the 22hydroxycholesterol 26-hydroxylase/ oxidase + CPR and 22(R)-hydroxycholesterol were divided
equally and used as substrate for 6 assays containing CYP90G1 + CPR and 6 assays
containing control cytochrome P450 + CPR. Extracts containing the enzymatic product of
CYP90G1 + CPR and 22(R)-hydroxycholesterol were divided and used as substrate in 6 assays
containing 22-hydroxycholesterol 26-hydroxylase/ oxidase + CPR and 6 assays containing
control cytochrome P450 + CPR. Control P450 + CPR assay was run in parallel, treated
identically and added to another control P450 assay. Assays were allowed to incubate for 20
min at 30°C then stopped by addition of 20 µl of 20% TCA with vortexing. Like assays were
pooled, extracted, derivatized, and analyzed by GC-MS using the protocol stated in
Experimental Procedures. Refer to Figure S11 a for an overview of the experiment.
Assay for LC-MS/MS: All assays used crude Sf9 cell suspensions. Enzyme assays started with
a combination of CYP90B27 + CPR and CYP94N1 + CPR (8 individual reactions) in parallel to
CYP90B27 + CPR and CYP90G1 + CPR (8 reactions). Assays were extracted, and added to
CYP94N1 + CPR, CYP90G1 + CPR, or GABAT1 for several possible enzyme combinations (4
reactions each). Like samples were pooled, extracted, and added to 2 reactions each with
enzyme not yet utilized previously. Refer to Figure S11 b for an overview of the experiment.
Samples were taken at each step post extraction for LC-MS/MS analysis and run by the
protocol stated in Experimental Procedures.

Method S9. Enzymatic product purification for NMR and high resolution MS for structure
elucidation.
Large-scale 750 ml S. frugiperda Sf9 cultures were grown expressing viral combinations 5-7
(Table S13) of the Veratrum californicum enzymes as previously described (Gesell et al. 2009).
Cells were collected after three days and re-suspended in 10 ml of 100 mM tricine pH 7.4/ 5 mM
thioglycolic acid; then extracted 3 times with 2 volumes of hexane or ethyl acetate. The
remaining aqueous supernatant was extracted once with 1 volume of hexane or ethyl acetate.
Extracts for each infection were then pooled, dried under N2, and re-suspended in 5 ml of
absolute methanol.
The extracts were purified on a Waters HPLC system equipped with a 2707 autosampler, 1525
binary pump, 2998 photodiode array detector, and Waters Fraction Collector III. In some cases,
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samples were cleaned up by Solid Phase Extraction (SPE), before HPLC purification. For
HPLC, extracts were concentrated to 500 µl and then injected in 50 µl portions onto a
Phenomenex Gemini C-18 NX column (150 X 2.00 mm, 5 µm) with the same solvents used for
LC-MS/MS as described in Experimental Procedures with the following binary gradient: Solvent
B was held at 20% for 2 min, then 2-11 min 20-30% B, 11-18 min 30-100% B, 18-30 min 100%
B, 30-31 min 100-20% B, and held at 20% B for an additional 5 minutes. The flow rate was 0.5
ml/min; 0.5 ml fractions were collected. The resulting fractions were then analyzed by GC-MS or
LC-MS/MS as described in Experimental Procedures, and selected samples were analyzed by
NMR or by high resolution MS. NMR spectra were acquired in MeOD at 600 MHz on a
BrukerAvance 600 MHz spectrometer equipped with a BrukerBioSpin TCI 1.7 mm
MicroCryoProbe. Proton, gCOSY, ROESY, gHSQC, and gHMBC spectra were acquired;

13

C

chemical shifts were obtained from the HSQC and HMBC spectra. Chemical shifts are reported
with respect to the residual non-deuterated MeOD signal. Refer to Data S2 for NMR
designations for 22-keto-cholesterol and 22-keto-26-hydroxycholesterol. For high resolution MS,
samples were diluted 1:10 in 80% acetonitrile:water (LC-MS grade) containing 0.1% formic acid
and infused into an LTQ-Orbitrap Velos Pro (Thermo-Fisher Scientific, San Jose, CA) using a
Triversa Nanomate (Advion, Ithaca, NY). Data were collected in positive ion mode, detected in
the Orbitrap at a nominal resolution setting of 60,000 at m/z 400. Precursors were determined
with a wide SIM scan (m/z 385-430). Precursors were isolated in the ion-trap and transferred to
the HCD cell for fragmentation at 35 NCE (m/z 418) and 50 NCE (m/z 398). Data were analyzed
manually using the Qualbrowser application of Xcalibur (Thermo-Fisher Scientific, San Jose,
CA).
Method S10. Phylogenetic analysis of cytochrome P450 enzymes across species using
deep transcriptome sequence data from 1KP and MonAToL projects.
Sequences for P450 genes were identified and pulled from various sources. Transcriptome data
for monocotyledon taxa were taken from the MonAToL project (DEB-0830020) and the 1KP
project (https://sites.google.com/a/ualberta.ca/onekp/home). Taxa were selected to represent
major clades but were not exhaustive of the sampling available. We also included genome
sequences from the 22 sequenced land plant genomes used by the Amborella genome project
to represent eudicots and other angiosperms (Amborella Genome 2013). The final taxa used in
reconstructing the P450 gene tree can be found in Table S8. Additionally, a P450 sequence
from S. cerevisiae was used as the outgroup (GenBank Accession: U34636.1).
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Transcriptomic data was assembled using Trinity r2013-02-25 and resulting assemblies were
filtered using FPKM (fragments per kilobase of exon per million fragments mapped). Sequences
where an isoform represented less than 1% of all reads mapping to a gene were discarded.
Assemblies were translated using the ORF estimation Transdecoder r20131110 software
packaged with Trinity. Blastp (Camacho et al. 2009) was used to blast genomic and
transcriptomic amino acid sequences using the S. lycopersicum GAME4, GAME6, GAME7, and
GAME8 (Refer to Table S7 for accession numbers) and Veratrum californicum CYP90B27,
CYP90G1, and CYP94N1 (Refer to Table S7 for accession numbers) P450 amino acid
sequence. Best blast hits were identified using an initial e-value threshold of 1e-10 followed by a
minimum overlapping length of 85% between the query and subject sequences. These filtering
criteria resulted in putative P450 genes of at least 1017 basepairs in length for all taxa.
Amino acid sequences for all putative P450 sequences were aligned using MAFFT v.7.029b
(Katoh and Standley 2014) under default settings. Trees were estimated using RAxML v.8.0.22
(Stamatakis 2006) under the GTR + Γ evolutionary model with 500 bootstrap replicates and S.
cerevisiae as the outgroup.
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Chapter 3: Production of Veratrum californicum secondary
metabolites in Camelina sativa seed
3.1 Summary
Economically feasible systems suitable for heterologous production of secondary metabolites
originating from complex species are in demand. Established systems such as Escherichia coli
and Saccharomyces cerevisiae are not always suitable for expression of plant and animals
genes due to several differences including mechanisms of post-translational modifications and
cellular organization. An emerging oilseed crop, Camelina sativa, has recently been engineered
to produce novel oil profiles, jet fuel precursors, and small molecules of industrial interest. One
medicinally relevant secondary metabolite, cyclopamine, is currently used to produce medicines
in clinical trials, and the future supply of this potential cancer treatment is uncertain. The sole
source of cyclopamine, Veratrum californicum, is slow growing and not amendable to cultivation.
In order to establish C. sativa as a system for the production of medicinally relevant compounds,
we introduced four genes from V. californicum involved in steroid alkaloid biosynthesis. These
four genes produce verazine, the hypothesized precursor to cyclopamine. Herein, we
successfully engineered C. sativa to produce verazine, as well as other V. californicum
secondary metabolites, in seed.
3.2 Significance statement
Verazine was produced in Camelina sativa seeds by heterologous expression of Veratrum
californicum genes CYP90B27, CYP94N1, CYP90G1, GABAT1 and the Arabidopsis thaliana
gene GAD2. This is the first report of verazine production in a heterologous system. In addition,
this is the first report of C. sativa use for the production of medicinally relevant compounds.
3.3 Author contributions
I, (Megan M. Augustin) in addition to Ashutosh K. Shukla and Cynthia Holland constructed
vectors for transformation. I performed all plant transformations and seed collection. I, with the
help of Linna Han, extracted seeds for metabolite analysis. I ran all samples on the LC-MS/MS
and analyzed the results. I generated all data for all figures. I produced all figures and wrote the
manuscript.
3.4 Introduction
Industrial production of plant derived natural products for medicinal use can be unachievable by
either traditional chemical synthesis or agricultural techniques. Chemical synthesis techniques
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often require harsh conditions and result in toxic byproducts. The complex stereochemistry of
many natural products can also complicate synthesis. In addition, direct extraction of medicinal
compounds from source plant species is not always a viable alternative, as many produce low
natural yields and/or not amendable to cultivation (Atanasov et al. 2015). The development of a
low input heterologous eukaryotic system is in demand for high value medicinal compounds.
One potential production system is the emerging agricultural oilseed crop Camelina sativa.
C. sativa is an attractive alternative to current heterologous production systems for plant natural
products such as Escherichia coli and Saccharomyces cerevisiae because of its molecular
compatibility with other plant species, as well as its low input requirements. The close
phylogenetic relatedness to the well-studied model organism Arabidopsis thaliana, in addition to
ease of transformation and a sequenced genome, offers a foundation of genetic and molecular
tools that can be utilized for metabolic manipulation (Kagale et al. 2014, Lu and Kang 2008).
Complication arising from codon usage and post-translational modifications would be minimal in
a plant production system as opposed to the distantly related microbial alternatives. Advantages
to cultivation of C. sativa include low water- and nutrient input, as well as its compatibility with
current agricultural practices (Putnam et al. 1993). In addition, its short growing season (ca. 100
days) along with cold tolerance has shown its potential for growth and harvest prior to the
normal growing season, therefore maximizing land use without effecting normal crop production
(Putnam et al. 1993).
C. sativa is under extensive investigation for its use in biofuel, industrial oil/lubricants, and high
value metabolite production. Genetic manipulation of fatty acid content by heterologous
expression of novel Cuphea FatB genes has altered fatty acid content in C. sativa by increasing
medium chain fatty acids, therefore mimicking the hydrocarbons present in Jet A fuel (Kim et al.
2015). Transgenic C. sativa was also shown to accumulate valuable liquid wax esters by
addition of wax ester synthase from Mus musculus or Simmondsia chinensis and fatty acyl-CoA
reductase from Mus musculus or Marinobacter aquaeolei (Iven et al. 2015). RNAi suppression
of C. sativa type 1 diacylglycerol acyltransferase led to accumulation of 3-acetyl-1,2-diacyl-snglycerols, triacylglycerols with attractive chemical properties including reduced freezing point
and viscosity (Liu et al. 2015). C. sativa has also been under investigation for the use in
aquafeeds as a replacement for vegetable oils that lack omega-3 long chain polyunsaturated
fatty acids (ω3 LC-PUFA). Accumulation of the highly desired ω3 LC-PUFA eicosapentaenoic
acid and docosahexaenoic acid has also been achieved by heterologous expression of yeast,
algae, and additional species’ genes involved in the delta6-desaturase pathway (Petrie et al.
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2014, Ruiz-Lopez et al. 2014). These high yielding ω3 LC-PUFA lines of C. sativa have been
shown to successfully replace fish oil in aquaculture (Betancor et al. 2015a, Betancor et al.
2015b). Non-genetically modified C. sativa has also shown promise in aquaculture (Hixson et al.
2013, Hixson et al. 2014a, Hixson et al. 2014b).
In addition to advances in oil composition, genetically manipulated C. sativa has shown promise
for the accumulation and storage of other highly valuable compounds. The production of the
mono- and sesquiterpenes limonene and cadinene (respectively), in transgenic C. sativa could
provide a robust and renewable source for these industrially useful terpenes, in addition to their
potential use in jet fuel (Augustin et al. 2015a). C. sativa was also engineered to produce the
biodegradable polymer poly-3-hydroxybutyrate (PHB). PHB can be used as a renewable
component in bio-plastics, among other industrial uses (Malik et al. 2015). Moreover, production
of these metabolites in seeds lends to easy harvest and long term storage, desirable traits for
large scale production. We hypothesize, based on the previous success of metabolic
engineering of C. sativa, that we can use C. sativa as a production system to produce
medicinally useful small metabolites in seed.
The stereochemically complex steroidal alkaloid cyclopamine is one medicinal compound
currently under clinical investigation whose supply is predicted to fall short of potential demands
upon FDA approval (Heretsch et al. 2010). Cyclopamine is best known for its teratogenic effects
in lambs born to pregnant ewes that ingested the source plant Veratrum californicum (Keeler
and Binns 1968). Cyclopamine’s mode of action is inhibition of the hedgehog pathway, mainly
active during embryonic development, by direct binding to the transmembrane receptor
Smoothend (Chen et al. 2002). Cyclopamine, and its semi-synthetic analog IPI-926, has shown
promise in cancer therapy where mutations in the hedgehog pathway cause over activation
leading to tumor growth, including pancreatic cancer, medulloblastoma, basal cell carcinoma,
leukemia, colon cancer, and small cell lung cancer (Bahra et al. 2012, Batsaikhan et al. 2014,
Berman et al. 2002, Jimeno et al. 2013, Lin et al. 2010, Olive et al. 2009, Taipale et al. 2000,
Tremblay et al. 2009, Watkins et al. 2003). Cultivation of V. californicum for production of
cyclopamine has yet to be successful, and cell cultures grow slowly and fail to produce
substantial amount of cyclopamine (Song et al. 2014). Four genes have been discovered in the
hypothesized biosynthetic pathway to cyclopamine (Augustin et al. 2015b). Together, the
enzymatic products of these genes convert cholesterol to the predicted cyclopamine steroidal
alkaloid precursor verazine. By transforming these four genes in addition to Arabidopsis
glutamate decarboxylase 2 (GAD2), an enzyme required to produce the co-substrate γ-
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aminobutyric acid (GABA) in seed, we have successfully engineered C. sativa to accumulate
verazine in seed (Turano and Fang 1998).
3.5 Results
3.5.1 Vector construction, plant transformation, and confirmation of construct integration
Vector construction for plant transformation consisted of two parts. The first gene was cloned
into an initial vector that contained a seed specific promoter and terminator. Next, the
expression cassette (consisting of the
promoter, gene, and terminator) was cut
out by restriction enzyme digest and
ligated into the multiple cloning site
(MCS) of the plant expression vector
pRSe3. Multiple expression cassettes
were then cloned into the MSC of one
plant transformation vector which
allowed several genes to be transformed
at once. Two plant expression vectors
were constructed. One contained three
genes involved in V. californicum steroid
alkaloid biosynthesis and was
designated CTOG (C= Cholesterol 22hydroxylase (CYP90B27), T= 22Hydroxycholesterol-26-al Transaminase
(GABAT1), O= 22-Hydroxycholesterol
26-hydroxylase/Oxidase (CYP94N1, and
G= Glutamate decarboxylase 2
(GAD2)). The second construct
contained four genes involved in V.
californicum steroid alkaloid
biosynthesis and was designated
CXTOG (X = 22-Hydroxy-26-aminocholesterol 22-oXidase (CYP90G1)). GAD2 was included in
both vector constructs in order to increase the concentration of GABA in seed, a co-substrate
required by GABAT1. The vector pRSe3 is a modified Ti (tumor inducing) plasmid from
Agrobacterium that allows for genomic integration of the DNA contained between the left and
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right border sequences (referred to as T-DNA), but does not allow for bacterial infection. The
vector also contains a Kanamycin resistance gene for selection in bacteria and the DsRed gene
for selection in C. sativa seed. C. sativa plants were transformed as previously described (Lu
and Kang 2008). Initial confirmation of T-DNA integration into transformed C. sativa was
achieved by visualization of DsRed by illuminating seeds with a green LED light and observing
fluorescence through a red filter. After transgenic seeds were grown to the next generation,
PCR analysis on selected CXTOG transgenic C. sativa confirmed integration of the construct
(Figure 1 A). Gene expression was also confirmed by PCR analysis on cDNA derived from total
developing seed RNA (Figure 1 B). In addition, production of metabolites as described below
supported integration and expression of the transgenes.
3.5.2 4000 QTRAP analysis for detection of V. californicum metabolites in transgenic C.
sativa seeds
Initial metabolite screening was performed on wild type and transgenic CTOG and CXTOG C.
sativa seed extracts using LC-MS/MS with a 4000 QTRAP for detection of verazine and
previously identified metabolites produced by the transgenes (Augustin et al. 2015b).
Accumulation of 22-hydroxy-26-aminocholesterol, in addition to three unknown compounds with
the same mass and similar fragmentation pattern, was detected in transgenic CTOG plants
containing CYP90B27, CYP94N1, GABAT1, and GAD2, but lacking CYP90G1 (Figure 2). 22Keto-26-hydroxycholesterol and verazine were not detected. In CXTOG plants containing
CYP90B27, CYP94N1, CYP90G1, GABAT1, and GAD2, 22-hydroxy-26-aminocholesterol was
not detected, but 22-keto-26-hydroxycholesterol was found to accumulate. In addition to this
compound, another peak eluted 1 minute later and appeared to have the same mass and
similar fragmentation pattern (Figure 3). A peak for verazine was detected by a more sensitive
scan (MRM scan) and appeared slightly above background and was not detected in the wild
type plants, but further analysis and verification was desired (Figure 4). In addition, a novel peak
eluted after verazine with the same fragment ion and was also not detected in the wild type or
Sf9 extracts.
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3.5.3 Q-Exactive analysis for
verazine detection
In order to verify the
accumulation of verazine in
CXTOG transgenic C. sativa
seeds, samples were analyzed
by high-resolution mass
spectrometry. The increased
sensitivity of the Q-Exactive
enhanced detection of verazine
and allowed us to obtain
accurate mass in addition to a
mass spectrum (Figure 5). The
detection of a peak with mass
398.3418 in the transgenic C.
sativa CXTOG extracts
coincided with verazine
produced in Sf9 cells. Both had
only 0.25 ppm and 0.5 ppm mass measurement error, respectively, when compared to the
calculated accurate mass of 398.3417. In addition, the defining fragment peak 126.1279 was
found in the transgenic plant samples as well as the verazine from Sf9 cells. This mass
corresponds to only 1.5 ppm mass measurement error when compared to the calculated
accurate mass of 126.1277. All mass measurement errors fall far below the 5 ppm limit for
determining compound identity. In addition to verazine, another metabolite with the same mass
and similar fragmentation pattern was also detected in the transgenic C. sativa extracts (Figure
5 F).
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3.6 Discussion
C. sativa engineered to express CYP90B27, CYP94N1, CYP90G1, GABAT1, and GAD2 was
shown to accumulate verazine, the hypothesized intermediate to the antineoplastic
cyclopamine. In addition to verazine, 22-keto-26-hydroxycholesterol was also detected.
Additional peaks with the same masses and similar fragmentation patterns occurred at different
retention times in planta for both of these compounds, suggesting the possibility of alternative
stereochemical isomers produced in C. sativa. Reduction/elimination of these side products may
be achieved by introducing sequential cyclopamine biosynthetic enzymes once they are
discovered. As described for A. thaliana engineered with three genes to produce dhurrin, a
cyanogenic glucoside from Sorghum, many unintended side products accumulated in transgenic
plants containing only two genes. When the third gene was introduced, and the pathway thereby
complete, the unintended side products were no longer detected and the end product was
greatly enhanced (Kristensen et al. 2005).
Despite the absence of true verazine quantitation (due to a lack of available standard), it was
observed that the production was quite low. Several possibilities exist for further engineering of
C. sativa for increased verazine and sequential metabolite production in the future. As
mentioned earlier, additional pathway enzymes may increase yield and drive the production of
metabolites with the correct stereochemistry. Another possibility would be to increase the
production of cholesterol in C. sativa, a precursor molecule for steroid alkaloids. Cholesterol has
been found as only a minor steroid in C. sativa, so this may be limiting for metabolite production
(Mansour et al. 2014). Overexpression of oxidosqualene cyclases such as cycloartenol
synthase or lanosterol synthase may increase the available cholesterol (Ohyama et al. 2009). In
addition, upregulation of bottleneck enzymes in the mevalonic acid pathway may enhance yield.
As previously demonstrated by Augustin et al.2015aq, overexpression of the rate limiting
enzyme 1-deoxy-d-xylulose-5-phosphate synthase (DXS) in C. sativa engineered to produce
limonene and cadinene significantly increased terpene production. A deeper understanding of
cholesterol biosynthesis in plants will enhance decisions in this regard. Engineering of this
pathway into another system such as S. cerevisiae is also a viable option, but would not include
the benefits of a C. sativa production system as described earlier.
Cultivation of C. sativa as an agricultural crop is industrially and environmentally attractive due
to its low input requirements and chemical properties. Efficient use of cultivatable land by
growing C. sativa prior to the typical growing season will provide an opportunity for metabolite
and fuel production without jeopardizing food crops or compromising undeveloped wilderness
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(Bansal and Durrett 2015). In addition, after metabolite extraction, the leftover material can be
utilized as biofuels or other industrial applications, wasting little material (Asomaning et al.
2014). Herein, we demonstrated the production of V. californicum secondary metabolites in C.
sativa, highlighting the possibilities for future engineering and industrial production.
3.7 Experimental procedures
Cloning and plant transformation
CYP90B27, CYP94N1, CYP90G1, and γ-aminobutyrate transaminase 1 (GABAT1) were cloned
from Veratrum californicum total root cDNA and glutamate decarboxylase 2 (GAD2) was cloned
from Arabidopsis thaliana (L.) Heyn., ecotype Columbia (Col-0) total leaf cDNA. V. californicum
plant tissues were obtained from wild collection in Northern Utah, USA and the Arabidopsis
tissue was obtained onsite (Donald Danforth Plant Science Center Greenhouse, St. Louis, MO,
USA). Total RNA from V. californicum was extracted as previously described (Johnson et al.
2012). Arabidopsis RNA was extracted using an RNeasy Plant Mini Kit (Qiagen). cDNA
synthesis followed using MMLV-RT. Genes were first ligated into cassette vectors to provide
each with a seed specific promoter and terminator before transfer into the plant expression
vector pRSe3, a binary vector with kanamycin and DsRed selection markers. pRSe3 is based
on pRSe2, with an enhanced multiple cloning site (Augustin et al. 2015a). The following genes
were ligated into each cassette vector providing the following seed specific
promoters/terminators: CYP90B27 (Oleosin/Oleosin); CYP94N1 (Napin/Glycinin); GABAT1
(Napin/Glycinin); CYP90G1 (Napin/Glycinin); and GAD2 (Glycinin/Glycinin). Final constructs
were made both with (CXTOG) and without (CTOG) CYP90G1. Plants were transformed as
previously described (Lu and Kang 2008). Transgenic seeds were screened as previously
described (Augustin et al. 2015a). Verazine, 22-keto-26-hydroxycholesterol, and 22-hydroxy-26aminocholesterol were heterologously produced in Sf9 insect cells as previously described
(Augustin et al. 2015b).
DNA extraction, RNA extraction, and PCR
DNA was extracted from leaf tissue of selected plants grown from seeds exhibiting red
fluorescence for verification of construct integration using the DNeasy Plant Mini Kit (Qiagen).
PCR was performed with primers GAD2_F_NdeI
(CACACATATGGTTTTGACAAAAACCGCAACGA), and GAD2_RC_NotI
(CACAGCGGCCGCTTAGCACACACCATTCATCTTCTT) and the following temperature
program parameters: 2 min 95 °C, 1 cycle; 30 s 95 °C, 30 s 52 °C, 1 min 72 °C, 30 cycles; final
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extension at 72 °C for 5 min. RNA was extracted from developing seeds with the RNeasy Plant
Mini Kit (Qiagen). cDNA synthesis followed using the RNA to cDNA EcoDry kit (Clontech) and
expression was confirmed by amplification of the GAD2 gene using the same primers and PCR
cycle described above. Amplification of tubulin was included as a control.
Seed extraction
T2 (CTOG) and T3 (CXTOG) generation seeds were extracted based upon the protocol in the
acyl-lipid metabolism chapter in The Arabidopsis Book (Li-Beisson et al. 2013). Hot isopropanol
(1.5 ml, 75°C) was added to 15-20 mg of seeds and incubated for 15 min. Seeds were then
crushed with a glass rod followed by the addition of chloroform and H2O (0.75 ml and 0.3 ml,
respectively). Next, samples were sonicated in a sonication bath for 10 min followed by robust
shaking for 1 hour at room temperature (RT). Tubes were then vortexed for 10 seconds and
centrifuged (1,500 x g, 2 min, RT). The liquid was moved to a fresh tube and the remaining
tissue was re-extracted once with 2 ml of chloroform:methanol (2:1) and once with 1 ml of
chloroform:methanol (2:1). Supernatants were combined prior to addition of 0.5 ml 1 M KCl.
Samples were vortexed, centrifuged, and the aqueous upper phase was removed. This
extraction was repeated once by the addition of 1 ml H2O. The organic phase was dried to
completion under N2. Extracts were re-suspended in 80% methanol and filtered with a 0.2 µ
PTFE filter (Millipore) before LC-MS/MS analysis.
LC-MS/MS analysis
Seed extracts were first analyzed by LC-MS/MS using a 4000 QTRAP (ABSciex) as previously
described (Augustin et al. 2015b). Selected seed extracts were additionally analyzed by highresolution mass spectrometry using a Q-Exactive (Thermo Fisher) coupled to an Agilent1200
microLC system. Samples were separated by a PLRP-S column (100 x 0.5 mm, 100Å, 3µ;
Higgins Analytical) with a flow rate of 15 µl/min and the following solvent/gradient system:
solvent A (0.05% formic acid/0.01% ammonium hydroxide v/v in H2O; solvent B (0.05% formic
acid/0.01% ammonium hydroxide v/v in 90% acetonitrile]: Solvent B was held at 10% for 4 min,
then 4-10 min 10-40% B, 10-18 min 40-45% B, 18-20 min 45-100% B, 20-21 min 100% B, 2122 100-10% B and held at 10% B for an additional 10 minutes. Results were analyzed using
Analyst 1.5 (Applied Biosystems) for data generated with the 4000 QTRAP and Xcalibur 3.0.36
(Thermo Scientific) for data generated by Q-Exactive.
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Chapter 4: Concluding remarks and future perspectives
With the conclusion of this work, four genes have been discovered in the biosynthesis of steroid
alkaloids in V. californicum. The enzymes encoded by these genes synthesize verazine from
cholesterol, a hypothesized intermediate of the antineoplastic cyclopamine. Verazine itself could
serve as a precursor molecule for the semi-synthesis of a variety of steroid alkaloids. The
enzymatic introduction of nitrogen can reduce the number of steps required to produce other
potentially useful steroid alkaloids that would otherwise require harsh chemical reactions
(Atanasov et al. 2015). Also of note, verazine has been shown to be a significant anti-fungal
agent, which could be useful for the development of novel anti-fungal treatments (Kusano et al.
1987).
The biosynthetic pathway to verazine, at least in this heterologous system, was clarified. The
pathway found herein is slightly different than what was predicted previously. The V.
californicum metabolite 22-keto-26-hydroxycholesterol does not appear to play a role in the
formation of verazine. It was also clarified that the C-22 position was hydroxylated first, followed
by hydroxylation at position C-26. We also established the nitrogen source for GABAT1 as
GABA, not arginine. In addition, oxidation at position C-22 must occur after nitrogen
incorporation, thus driving the formation of the piperidine ring. We also found that gene
expression does not entirely overlap with the accumulation of cyclopamine. These enzymes
may be involved in the formation of additional steroid alkaloids in V. californicum, as the plant
makes several types which may all rely on these initial biosynthetic genes. These discoveries,
however, are only the beginning for future cyclopamine production.
Continued research is necessary for complete elucidation of this pathway. As the semi-synthetic
analog IPI-926 proceeds in clinical trials, and the prospects of cyclopamine and its derivatives
remain high for cancer treatment, the demand for this compound will outweigh the supply.
Several more complex steps are required to form cyclopamine from verazine including
hydroxylation at position C-16 followed by closure of the E-ring. Hydroxylation at position C-12
must follow, preceding the notable ring rearrangement for formation of the C-nor-D-homo
skeleton. Opening and closing of the E-ring must occur with the addition of an oxygen atom
before cyclopamine can be formed as well. Once these genes have been discovered, future
work on cyclopamine production at an industrial level can be continued. The synthesis of IPI926, however, could possibly initiate from one of the cyclopamine precursors, and full pathway
elucidation may not be required.
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In addition, it has been demonstrated that the V. californicum genes CYP90B27, CYP94N1,
CYP90G1, and GABAT1 are functional in the heterologous expression system C. sativa.
Accumulation of verazine was confirmed in transgenic seed. Continued efforts are necessary to
increase production and overcome bottlenecks, but the basis for production has been
established. Moreover, the use of C. sativa as a heterologous production system for medicinally
useful metabolites has been explored and is supported by the work herein. Future work on C.
sativa, in conjunction with the vast knowledge base from the close relative A. thaliana, can help
achieve greater accumulation of metabolites by manipulation of primary metabolic pathways.
New technologies, such as RNAi, can help downregulate specific genes without eliminating
them completely, allowing for the fine tuning of metabolic pathways for optimal metabolite
production. C. sativa will, however, remain in the infancy stage as a production system unless
more focus is placed on this crop and its potential is fully explored.
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